Agreed terms 7 1 Interpretation 7 1.1 Definitions 7 1.2 Construction 12 1.3 Headings 13 2 Action Taken after Effective Date 13 3 License 13 3.1 Grant of License 13 3.2 LifeScan rights 13 4 Joint Steering Committee 13 4.1 Establishment 13 4.2 Composition 14 4.3 Decision making 14 5 Supply of Products 14 5.1 Supply of Initial Products 14 5.2 Supply of Other Products 15 6 Purchase Price of Initial Products 15 6.1 Interim Costing Period 15 6.2 Post-Interim Costing Period 16 7 Orders, Inventory and Delivery 18 7.1 Forecasts and orders 18 7.2 Inventory 19 7.3 Lead Time 19 7.4 Past Due Orders 19 7.5 Delivery 19 7.6 Sub-Tier Component Supply Chain 19 7.7 Packaging for Shipment 20 7.8 Quarterly Business Reviews 20 7.9 Capacity 20 7.10 Supply Risk 20 8 Defective Products 20 8.1 Disposition of defective Products 20 8.2 Independent testing 21 8.3 Corrective action 22 9 Inspection 22 9.1 Rights of Inspection 22 9.2 Obligations to rectify 22 9.3 Acknowledgment 22 page 2

Exhibit 10.1

EXECUTION COPY

Date: 29 October 2007

LifeScan, Inc.

Universal Biosensors Pty Ltd

Universal Biosensors, Inc.

Master Services and Supply Agreement

Table of Contents

Agreed terms			7
1 Interpretation			7
1.1 Definitions			7
1.2 Construction			12
1.3 Headings			13
2 Action Taken after Effective Date			13
3 License			13
3.1 Grant of License			13
3.2 LifeScan rights			13
4 Joint Steering Committee			13
4.1 Establishment			13
4.2 Composition			14
4.3 Decision making			14
5 Supply of Products			14
5.1 Supply of Initial Products			14
5.2 Supply of Other Products			15
6 Purchase Price of Initial Products			15
6.1 Interim Costing Period			15
6.2 Post-Interim Costing Period			16
7 Orders, Inventory and Delivery			18
7.1 Forecasts and orders			18
7.2 Inventory			19
7.3 Lead Time			19
7.4 Past Due Orders			19
7.5 Delivery			19
7.6 Sub-Tier Component Supply Chain			19
7.7 Packaging for Shipment			20
7.8 Quarterly Business Reviews			20
7.9 Capacity			20
7.10 Supply Risk			20
8 Defective Products			20
8.1 Disposition of defective Products			20
8.2 Independent testing			21
8.3 Corrective action			22
9 Inspection			22
9.1 Rights of Inspection			22
9.2 Obligations to rectify			22
9.3 Acknowledgment			22

10 Provision of Services			23
10.1 Supply of Initial Services			23
10.2 Supply of other Services			23
10.3 Manner of performing the Services			23
11 Fees			24
11.1 Quarterly Service Fee			24
11.2 Milestones			25
11.3 Lump Sum Service Fee			25
11.4 Audit Rights			26
12 Manufacturing Process Information and Other Intellectual Property			26
13 Sundry Obligations of UBS			27
13.1 Records			27
13.2 Reports			27
13.3 Equipment			27
13.4 Insurance			28
14 Restrictions on UBS and UBI activities			28
15 Representations and warranties			28
15.1 UBS Warranties			28
15.2 Execution and performance of agreement			29
15.3 EXCLUSION OF OTHER WARRANTIES			29
16 Compliance			30
16.1 Compliance with certain laws			30
16.2 Compliance with Policy on the Employment of Young Persons			30
16.3 Standards for Responsible External Manufacturing			30
16.4 Files and Work papers			31
16.5 Compliance with Environment, Safety And Industrial Hygiene			31
17 Quality Agreement			32
18 Indemnities			32
18.1 UBS indemnity			32
18.2 Indemnification by LifeScan			32
18.3 Indemnification procedures			33
18.4 Other Product Liability Claims			33
18.5 Limitation of Liability			33
19 Term and Termination			34
19.1 Term			34
19.2 Termination for breach			34
19.3 Termination for insolvency and bankruptcy			34
19.4 Termination for change of control			34
19.5 Regulatory termination			34
19.6 Additional LifeScan termination rights			34
19.7 Additional UBS termination rights			35
19.8 Consequences of termination			35

20 Dispute Resolution			36
20.1 Mediation			36
20.2 Arbitration			37
21 Confidentiality and public announcements			40
21.1 Non-disclosure			40
21.2 Exceptions			40
21.3 Public Announcements			40
22 Notices			41
22.1 General			41
22.2 How to give a communication			41
22.3 Particulars for delivery of notices			41
22.4 Communications by post or international courier			43
22.5 Communications by fax			43
22.6 After hours communications			43
22.7 Process service			43
23 Force Majeure			43
23.1 Force Majeure Event			43
23.2 Failure to supply			44
24 Guarantee			44
24.1 Guarantee and Indemnity			44
24.2 Survival			45
24.3 Continuing Guarantee			45
24.4 Remedy			45
24.5 Reinstatement			46
24.6 Warranties			46
25 GST			46
25.1 Construction			46
25.2 Consideration GST exclusive			46
25.3 Payment of GST			46
25.4 Timing of GST payment			47
25.5 Tax invoice			47
25.6 Adjustment event			47
25.7 Reimbursements			47
26 General			47
26.1 Duty			47
26.2 Legal costs			48
26.3 Amendment			48
26.4 Waiver and exercise of rights			48
26.5 Rights cumulative			48
26.6 Consents			48
26.7 Governing law and jurisdiction			48
26.8 Assignment			48

26.9 Counterparts			49
26.10 Entire understanding			49
26.11 Severability			49
26.12 Survival			49
26.13 Relationship of parties			49
26.14 LifeScan Affiliates			50
Schedule 1 — Initial Product Addendum			51
Schedule 2 — Initial Services Addendum			55
Schedule 3 — LifeScan Relevant Patents			58
Appendix A — Form of Product Addendum			60
Appendix B — Form of Services Addendum			62
Appendix C — Initial Joint Steering Committee Members			64
Appendix D — Policy on the Employment of Young Persons			65
Appendix E — Quality Agreement			66
Appendix F — Financial Years			78
Appendix G — UBS’ Insurance Requirements			89
Appendix H — Termination Matters			91
Appendix I — Action Taken after Effective Date			92
Appendix J — Standards for Responsible External Manufacturing			93

Effective Date: 29 October 2007

Parties

LifeScan, Inc. a California corporation of 1000 Gibraltar Drive, Milpitas, CA 95035-6312, USA (LifeScan)

Universal Biosensors Pty Ltd ACN 098 234 309, a company incorporated in Victoria, Australia of 1 Corporate Avenue, Rowville, Victoria 3178, Australia (UBS)

Universal Biosensors, Inc., a Delaware corporation of having its registered office at c/o Corporation Service Company 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808, USA (UBI)

Background

A. LifeScan carries on the business of marketing and selling blood glucose monitoring systems for home, clinic and hospital use.

B. UBS carries on the business of researching, developing, manufacturing and commercialising a range of in vitro diagnostic tests for point of care use.

C. LifeScan holds certain patents and other intellectual property rights relating to innovative blood glucose testing devices and wishes to distribute strips and meters as part of a new range of its blood glucose monitoring systems.

D. LifeScan and UBI are parties to a Development Agreement, under which UBS has been developing certain strips, meters and manufacturing methodology for LifeScan.

E. UBS has developed the capability and established a facility to manufacture and supply such strips to LifeScan.

F. UBS further has the expertise and information to provide a range of services of interest to LifeScan, including services relating to the development and testing of strips, the development and establishment of manufacturing facilities for strips and the development of variants and future generations of strips and meters.

G. The parties wish to enter into an agreement in relation to the provision by UBS to LifeScan of Initial Product and Initial Services, and other Product and other Services which LifeScan in the future may require from time to time.

H Whereas UBS is entitled to various payment streams under this Agreement which are intended to enable UBS to recover its sunk costs and make a reasonable return.

I To facilitate an efficient and effective business and contractual relationship between the parties, they have agreed to establish a Joint Steering Committee.

J For these purposes the parties have agreed to enter into this Master Services and Supply Agreement to regulate, on the terms and subject to the conditions set out in this agreement, the relationship between the parties and the provision by UBS of all such products and services to LifeScan.

K. UBI has agreed to guarantee UBS’ obligations under this Agreement.

In consideration of the mutual promises, covenants and agreements below, the parties agree as follows:

Agreed terms

Part 1: Preliminary Provisions

1		Interpretation
1.1		Definitions
		In this Agreement:
		Affiliate means any corporation, firm, limited liability company, partnership, or other entity that directly or indirectly controls, or is controlled by, or is under common control with a party to this agreement but only for so long as that control remains, whereafter that entity shall cease to be an Affiliate. For the purpose of this definition, control means ownership, directly or through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors in the case of a corporation, or fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, or status as a general partner in any partnership, or any other arrangement whereby a party controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity.
		Agreed Standard Cost has the meaning given in clause 6.2(b)(i) of this Agreement.
		Agreement Intellectual Property Rights has the meaning given in clause 12(c) of this Agreement.
		Bankruptcy Event means in respect of LifeScan or UBI: (i) it applies for or consents to the appointment of, or the taking of possession by, a receiver, custodian, trustee or liquidator of itself or of all or a substantial part of its property, (ii) it makes a general assignment for the benefit of its creditors, or (iii) it takes any action to take advantage of, or have any action taken against it under, any U.S. law relating to bankruptcy, insolvency or reorganization.
		Base Year has the meaning given in clause 6.2(a) of this agreement.
		Base Year Standard Cost has the meaning given in the Initial Product Addendum.

Business Day means a day which is not a Saturday, Sunday or bank or public holiday in New York City, New York, U.S.A.

Change of Control means (a) the liquidation or dissolution of an entity or the sale or other transfer by an entity (excluding transfers to Affiliates) of all or substantially all of its assets; or (b) the occurrence of a tender offer, stock purchase, other stock acquisition, merger, consolidation, recapitalization, reverse split, sale or transfer of assets or other transaction, as a result of which any person, entity or group (other than an Affiliate of such entity prior to such transaction) (i) becomes the beneficial owner, directly or indirectly, of securities of an entity representing more than 50% of the ordinary shares such entity or representing more than 50% of the combined voting power with respect to the election of directors (or members of any other governing body) of such entity’s then outstanding securities, (ii) obtains the ability to appoint a majority of the Board of Directors (or other governing body) of the entity, or (iii) obtains the ability to direct the operations or management of the entity or any successor to the entity’s business.

Confidential Information means:

	(a)		the terms and existence of this Agreement; and
	(b)		all confidential and proprietary information in whatever form or manner presented which is disclosed pursuant to this Agreement or any Product Addendum or Services Addendum and which relates to a disclosing party’s business or business plans.

Corporations Act means the Corporations Act 2001 (Cth).

Cost Savings Amount has the meaning given in clause 6.2(b)(ii) of this Agreement.

Covered Product means any Product covered by at least one valid claim of the LifeScan Relevant Patents.

Development Agreement means the development and research agreement between UBI and LifeScan, effective as of April 1, 2002, and any and all amendments thereto.

Effective Date means the date on the first page of this Agreement.

Fee Conversion Reference Date means the end of the Quarter following the receipt by UBS of an aggregate of
*[REDACTED] in Quarterly Service Fees.

Financial Year means LifeScan’s fiscal year, as defined in Johnson & Johnson’s internal accounting policies and procedures, which ends on the last Sunday of any given Calendar Year. Appendix F sets forth the applicable Financial Years through 2013.

Force Majeure Event means any cause which is beyond the reasonable control of a party, including fire, explosion, flood, or other acts of God; acts, regulations, or laws of any government; war or civil commotion; strike, lock-out or labour disturbances, failure of public utilities or common carriers.

Government Authority means any relevant federal, state, territory, municipality or other political subdivision, administrative or judicial body, court, ministry, department, commission, authority, instrumentality, tribunal or agency or other governmental, quasi-governmental or regulatory authority or any self-regulatory organisation (including any relevant tax administrator) of any applicable country and includes any person deriving a power directly or indirectly from any other person or body referred to in this definition.

Initial Meter means a blood glucose meter adapted to use the Initial Product and conforming to the specifications set out in the Initial Product Addendum

Initial Product means a blood testing strip which conforms with the Product Specifications set out in the Initial Product Addendum.

Initial Product Addendum means the Addendum set out in Schedule 1.

Initial Services means the services described in Schedule 2.

Initial System means the blood glucose monitoring system consisting of the Initial Meter, Initial Product, control solution, lancets and all other applicable components.

Insolvency Event means in respect of UBS:

	(a)		it is (or states that it is) an insolvent under administration or insolvent (each as defined in the Corporations Act);
	(b)		it has had a controller (as defined in the Corporations Act) appointed or is in liquidation, in provisional liquidation, under administration or wound up or has had a receiver or a receiver and manager appointed to any part of its property;
	(c)		it is subject to any arrangement, assignment, moratorium or composition, protected from creditors under any statute or dissolved (in each case, other than to carry out a reconstruction or amalgamation while solvent on terms approved by the other parties to this Agreement);
	(d)		an application or order has been made (and in the case of an application, it is not stayed, withdrawn or dismissed within 30 days), resolution passed, proposal put forward, or any other action taken, in each case in connection with that person, which is preparatory to or could result in any of (a), (b) or (c) above;
	(e)		it is taken (under section 459F(1) of the Corporations Act) to have failed to comply with a statutory demand;
	(f)		it is the subject of an event described in section 459C(2)(b) or section 585 of the Corporations Act;
	(g)		it is otherwise unable to pay its debts when they fall due; or
	(h)		something having a substantially similar effect to (a) to (g) happens in connection with UBS under the laws of Australia.

Interim Costing Period means the period beginning upon the commencement of manufacturing following the submission of LifeScan’s first order for commercial launch of the Initial Product until the earlier of (i) the beginning of the first Quarter in which LifeScan places an order in excess of fifty million (50,000,000) Initial Products or (ii) the end of the Quarter during which the third anniversary of the achievement of a Milestone occurs.

Joint Steering Committee has the meaning given in clause 4.1 of this Agreement.

Joint Steering Committee Member has the meaning given in clause 4.2 of this Agreement.

Labour and Overhead Costs means actual labour and overhead costs assignable to the manufacturing of Initial Product.

License Agreement means the license agreement between UBS and LifeScan, effective as of 1 April 2002, and any and all amendments thereto.

Licensed Intellectual Property Rights means any and all LifeScan Intellectual Property Rights required by, or reasonably necessary for, UBS to fulfil its obligations under this Agreement.

LifeScan Files and Work Papers has the meaning given in clause 16.4 of this Agreement.

LifeScan Intellectual Property Rights means any and all intellectual property rights throughout the world, including:

	(a)		any patent, copyright, trade secret, know-how, technology, trade mark or domain name (whether registered or unregistered), software, design, circuit layout right, trade, business or company name or other proprietary right or any right to registration of such rights; and
	(b)		all present and future rights in an invention, discovery, trade secret, know-how, concept, idea, data or formula and rights in information, including any serendipitous discoveries, granted by law or equity from time to time under the law of any jurisdiction which LifeScan owns or is empowered to grant a license prior to or during the Term of this Agreement. LifeScan Intellectual Property Rights shall further include any foreign counterparts thereof, as well as all continuations, continuation-in-part, divisions and renewals thereof, patent applications, all patents which may be granted thereof, and all reissues, re-examinations and extensions.

LifeScan Manufacturing Line Date means the date that LifeScan, a LifeScan Affiliate or a contract manufacturer of LifeScan shall have qualified a manufacturing line that is actually capable of producing the Initial Product in a place other than Rowville, Victoria.

LifeScan Relevant Patents means those patents and patent applications identified on Schedule 3, as well as any United States patent application, foreign counterpart, division, continuation, continuation-in-part, reissue, renewal, and re-examination thereof and patents issuing therefrom, patent extensions, certificates of invention and applications for certificates of invention.

Losses means any losses, liabilities, damages, claims, costs, charges and expenses and includes any taxes, duties, levies, legal fees (on a full indemnity basis) and other related expenses.

Lump Sum Service Fee — A has the meaning given in clause 11.3(a) of this Agreement.

Lump Sum Services Fee — B has the meaning given in clause 11.3(c) of this Agreement.

Material Costs means the cost of material comprising the Initial Product that is consumed during the manufacturing of the Initial Product (e.g. substrates and spacer), excluding the cost of the vials and enzymes.

Maximum Transfer Price means the cost per Initial Product set forth in the Initial Product Addendum.

Milestone means the grant to LifeScan or its nominated Affiliate of regulatory approval to market the Initial System in (a) Canada; (b) the United States; and (c) Germany or the first other European country where LifeScan chooses to market the Initial Product, each such approval constituting a separate Milestone.

Milestone Amount has the meaning given in clause 11.2(a) of this Agreement.

Policy has the meaning given in clause 16.2 of this Agreement.

Process has the meaning given in clause 12 of this Agreement.

Product means a strip which conforms with the relevant Product Specification, and includes the Initial Product and any additional products that the parties agree to include in a Product Addendum.

Product Addendum means a document executed by the parties for Product to be manufactured pursuant to the terms of this Agreement substantially in the form set out in Appendix A.

Product Specifications means:

	(a)		in the case of the Initial Product, the specifications set out in Schedule 1;
	(b)		in the case of any other Product, the specifications set out in the relevant Product Addendum.

QSR means the quality system regulations applicable to a Product.

Quality Agreement means the quality agreement attached as Appendix E of this Agreement.

Quarter means in respect of any Financial Year, the quarter end designated by a circle on Appendix F for such Financial Year.

Quarterly Service Fee has the meaning given in clause 11.1(a)(i) of this Agreement.

		Raw Materials means the materials, components and packaging required to manufacture and package the Products in accordance with the Product Specifications.
		Restricted Purposes has the meaning given in clause 14(a) of this Agreement.
		Services means the services described in Schedule 2 and any other services identified in a Services Addendum.
		Services Addendum means a document executed by the parties for services to be provided by UBS to LifeScan pursuant to the terms of this Agreement, substantially in the form set out in Appendix B.
		Sold means the sale or other transfer of Product by LifeScan or any of its Affiliates to an unaffiliated third party that generates direct sales revenue to LifeScan or any of its Affiliates.
		Standards has the meaning given in clause 16.3 of this Agreement.
		Term has the meaning given in clause 19.1 of this Agreement.
		Territory means the entire world.
		UBS Capacity Limitation has the meaning given in clause 7.1(a).
1.2		Construction
		Unless expressed to the contrary, in this Agreement:

	(a)		words in the singular include the plural and vice versa;
	(b)		any gender includes the other genders;
	(c)		if a word or phrase is defined its other grammatical forms have corresponding meanings;
	(d)		“includes” (and its variants, i.e., “include” and “including”) means includes without limitation;
	(e)		no rule of construction will apply to a clause to the disadvantage of a party merely because that party put forward the clause or would otherwise benefit from it; and
	(f)		a reference to:

	(i)		a person includes a partnership, joint venture, unincorporated association, corporation and a government or statutory body or authority;
	(ii)		a person includes the person’s legal personal representatives, successors, assigns and persons substituted by novation;
	(iii)		any legislation includes subordinate legislation under it and includes that legislation and subordinate legislation as modified or replaced; and

(iv)

an obligation includes a warranty or representation and a reference to a failure to comply with an obligation includes a breach of warranty or representation.

(g)

“$” or “dollar” means the lawful currency of the United States unless otherwise expressly stated.

1.3		Headings
		Headings do not affect the interpretation of this Agreement.
2		Action Taken after Effective Date
		After the Effective Date but on or before January 15, 2008, and in consideration of the grant of rights in clause 12, LifeScan shall take the action prescribed in Appendix I.
3		License
3.1		Grant of License
		LifeScan grants to UBS during the Term of this Agreement a worldwide, royalty free, non-exclusive license to use Licensed Intellectual Property Rights for the sole purpose of fulfilling its obligations under this Agreement.
3.2		LifeScan rights

	(a)		Nothing in this Agreement shall be construed to restrict the right of LifeScan or LifeScan’s Affiliates to engage in any business activity, investment or other opportunity anywhere in the world. UBS acknowledges LifeScan shall have sole discretion where and how to market and sell the Products.
	(b)		UBS acknowledges and agrees that LifeScan and its Affiliates are, and will continue to be, actively involved in the design, development, acquisition, marketing, manufacturing, promotion and sale of blood glucose monitoring products, including products that directly and indirectly compete with the Products hereunder.

4

Joint Steering Committee

4.1		Establishment
		Within 30 Business Days of the Effective Date, a joint committee (Joint Steering Committee) shall be established to manage the relationship between the parties and the operation of this Agreement. The Joint Steering Committee shall provide strategic oversight of the performance of the parties’ obligations and the progress of the Products and Services provided under this Agreement. The Joint Steering Committee shall have the power to create and delegate responsibility to various working groups compromised of members from the parties to carry out its obligations under this Agreement.

4.2		Composition
		The Joint Steering Committee shall consist of members (Joint Steering Committee Members) from each of UBS and LifeScan. The Joint Steering Committee Members shall be comprised of senior management from each party (and the initial Joint Steering Committee members are set out in Appendix C). Each party may change their nominated Joint Steering Committee Member by written notice to the other party. The Joint Steering Committee shall convene on a quarterly basis, to review and approve work plans and progress. Additionally, the Joint Steering Committee shall be available on a more frequent basis to address key issues that may arise. All meetings of the Joint Steering Committee may be by teleconference, videoconference or any other means of communication agreed to by the parties.
4.3		Decision making

	(a)		Each of UBS and LifeScan shall have one vote on the Joint Steering Committee. If more than one representative of a party is present at a meeting, such representatives shall agree upon how that party’s vote shall be cast. If only one representative is present, that party shall be deemed authorized to vote on the matters raised at the meeting. All decisions of the Joint Steering Committee shall be unanimous.
	(b)		No decision may be made by the Joint Steering Committee unless a quorum is present, such quorum constituted by at least one member present from each of LifeScan and UBS.
	(c)		If the Joint Steering Committee is unable to reach Agreement on any significant matter, then within ten Business Days it shall be referred to the Company Group Chairperson of LifeScan and the Chairperson of UBS and they shall endeavour to resolve such matter in good faith within twenty Business Days of notification by the Joint Steering Committee of the disagreement. If the Chairpersons are unable to reach an Agreement on the matter: (i) with respect to any matter involving the quality of the Products, regulatory affairs relating to the Products or any matter that could require expenditures of funds by LifeScan in addition to those already contemplated by this Agreement, LifeScan shall have the right to make the decision; and (ii) with respect to all matters not covered by clause (i), the matter shall be resolved pursuant to the provisions of clause 20 of this Agreement.

		Part 2: Products
5		Supply of Products
5.1		Supply of Initial Products

(a)

UBS will supply LifeScan or its designates with Initial Products in accordance with and subject to the terms of this Agreement.

(b)

Except for binding orders placed in accordance with clause 7.1(c), LifeScan is not obligated to obtain supply of the Initial Products or any other Products exclusively, or at all, from UBS. Further, LifeScan shall have the right to obtain supply of the Initial Products or any other Products solely from its own manufacturing facilities or from any Affiliate or third party supplier at any time.

5.2

Supply of Other Products

	(a)		From time to time the parties may agree that UBS will develop and / or manufacture and supply additional Products to LifeScan. For purposes of clarification, the Joint Steering Committee would agree on additional products, cost recovery and success fees based on milestones achieved. In each such event, the parties shall enter into a Product Addendum.
	(b)		Each Product Addendum, when executed will be attached to this Agreement and form part of and be subject to the terms of this Agreement.
	(c)		During the term of each Product Addendum, UBS will manufacture and supply to LifeScan the Products specified in that Product Addendum in accordance with and subject to the terms of this Agreement.
	(d)		In the event of a conflict between the terms of this Agreement and the terms of any Product Addendum, the terms of this Agreement will prevail, except to the extent that the applicable Product Addendum expressly and specifically states an intention to supersede this Agreement on a specific matter.
	(e)		If a Product Addendum provides for the amendment of a term of this Agreement, that amendment will be effective only in relation to that Product Addendum and, unless expressly specified to the contrary in the Product Addendum, will not otherwise amend this Agreement or operate in relation to any other Product Addendum or Services Addendum.

6		Purchase Price of Initial Products
6.1		Interim Costing Period
		During the Interim Costing Period, LifeScan must pay to UBS in respect of each Initial Product supplied by UBS to LifeScan or any of its designates:

	(a)		* [REDACTED]; and
	(b)		* [REDACTED]

UBS shall use its best efforts to minimize the amount of * [REDACTED] during the Interim Costing Period. In no event shall the aggregate amount due under clause 6.1(a) above for all Initial Products supplied in a given Quarter exceed *[REDACTED]. LifeScan acknowledges and agrees that it has requested UBS to obtain raw materials components known as enzymes and vials at its expense and they shall not be included in the above cap and further provided that UBS is permitted to include the cost of any enzyme and vials consumed in the manufacturing process in any invoice for Initial Product.

6.2

Post-Interim Costing Period

	(a)		From the period beginning upon the end of the Interim Costing Period through the end of the then current Financial Year (Base Year), the standard cost of manufacturing an Initial Product to LifeScan shall be equal to the Base Year Standard Cost. For the avoidance of doubt, such Base Year Standard Cost excludes the cost of the enzymes and vials.
	(b)		In June of each year, commencing with the Base Year the parties will meet and by July 1st (provided, that if the Base Year commences after June, then the parties shall meet as soon as reasonably possible):

	(i)		agree upon the standard cost of Initial Product to apply for the following Financial Year (Agreed Standard Cost) taking into account: (A) all relevant costing and manufacturing information, which shall be supplied by UBS along with reasonable supporting data, (B) assuming a volume of Initial Products equal to LifeScan’s forecasted volume for such Financial Year; and (C) excluding the cost of the enzyme and vials; and
	(ii)		compare the Agreed Standard Cost against the Base Year Standard Cost for the purposes of determining whether the Agreed Standard Cost is less than the Base Year Standard Cost, in which case the amount of the relevant difference is the Cost Savings Amount.

(c)

Subject to clauses 6.2(d) and 6.2(e), in respect of each Financial Year commencing with the Base Year, LifeScan must pay to UBS in respect of each Initial Product supplied by UBS to LifeScan an amount equal to:

	(i)		the standard cost applicable for that year as determined in accordance with clause 6.2(a) or clause 6.2(b);
	(ii)		plus an amount equal to * [REDACTED] of the portion of the standard cost of an Initial Product which is not attributable to the cost of Material Costs; and
	(iii)		plus * [REDACTED] of the Cost Savings Amount if applicable.

			LifeScan shall in addition pay to UBS an amount for enzymes and vials in accordance with clause 6.2(f).
	(d)		The amount that LifeScan shall be obligated to pay UBS in aggregate for each Initial Product shall in no event exceed the Maximum Transfer Price plus the cost of enzyme and vials, provided, that if in any Quarter following the end of the Interim Costing Period, LifeScan orders less than 50 million Initial Products from UBS, clause 6.2(c) will not apply in respect of that Quarter and LifeScan will pay UBS for the relevant Initial Products in accordance with the costing methodology set out in clause 6.1.

	(e)		If there are factors outside the reasonable control of UBS that adversely affect UBS’ ability to provide the Initial Product at a total cost that does not exceed the Maximum Transfer Price plus the cost of the enzyme and vials, the Joint Steering Committee will meet to consider a suspension or ongoing change to the Maximum Transfer Price. If the parties cannot reach Agreement then the provisions of clause 6.2(d) will apply and UBS may terminate this Agreement in accordance with clause 19.7(b) or such shorter period as may be agreed by the parties.
	(f)		LifeScan acknowledges and agrees that it has requested UBS to obtain raw materials components known as enzymes and vials at its expense and that UBS is permitted to include the actual cost paid by UBS of any enzyme and vials consumed in the manufacturing process in any invoice for Initial Product. Such costs shall be excluded from the calculations of the Base Year Standard Cost, the Agreed Standard Cost and the Cost Savings Amount.
	(g)		UBS shall invoice LifeScan for all payments due under this clause 6 with such frequency as is mutually acceptable to the parties. All payments under this clause 6 shall be payable by LifeScan within 45 days of receipt of an undisputed invoice in immediately available funds. LifeScan shall notify UBS promptly of any portion of an invoice it disputes and, subject to the then current capability of the Accounts Payable system of LifeScan, LifeScan shall pay the undisputed portion of such invoice while the dispute is being resolved.
	(h)		In order to support timely invoice processing UBS shall use commercially reasonable efforts to ensure that: (i) the quantity of Products(s) shipped does not exceed the quantity of Products ordered pursuant to the relevant purchase order, (ii) the invoice sent by UBS to LifeScan reflects the correct LifeScan purchase order number to which it relates, (iii) the unit pricing on the invoices matches the unit pricing reflected on the purchase order to which it relates, and (iv) each invoice shall reflect no more than one purchase order number.
	(i)		During the term of this Agreement, the parties agree to make all commercially reasonable efforts to achieve cost reductions in cooperation with one another through the continuous improvement of either party’s production, procurement and supply processes in addition to any other general improved efficiencies achieved by such party such as those based on labor efficiencies and volume provided to the extent LifeScan is utilizing the services of a third party vendor or contract manufacturer and is prohibited from sharing those cost reductions with UBS, then it shall not be required to do so. The foregoing notwithstanding, UBS shall in no event modify or substitute any materials, components or processes used in the production, procurement or supply of any Product without the prior written consent of LifeScan, which shall not be unreasonably withheld. No such change shall in any way affect the safety or quality of any Product, and all such changes shall conform to a QSR compliant change control process mutually agreed to by UBS and LifeScan.

(j)

UBS shall keep complete and accurate records in sufficient detail to evidence its costs and support for its invoices provided to LifeScan (the “Financial Records”). For the sole purpose of verifying amounts owed under such invoices, LifeScan (or its designated audit expert) shall have the right no more than one time each calendar year, at its own expense, to review the Financial Records for the preceding Quarters during the Term (other than those already reviewed in a prior audit) at the location(s) where the Financial Records are maintained by UBS upon thirty (30) days notice and during regular business hours. Results of such review shall be made available to UBS. Further, if the review reflects an overpayment to UBS, such overpayment shall be credited against the next payment due UBS. If the overpayment is greater than five percent (5%) of the amount that was otherwise due for a Quarter, UBS shall reimburse LifeScan for the costs of such review. If no further payments are due to UBS (e.g. due to termination of this Agreement), then UBS shall pay to LifeScan the amount of such overpayment within forty-five (45) days of LifeScan’s provision to UBS of the results of LifeScan’s review. If the review reflects an underpayment to UBS, such underpayment shall be remitted by LifeScan to UBS within forty-five (45) days.

7		Orders, Inventory and Delivery
7.1		Forecasts and orders

	(a)		On a monthly basis during the Term, LifeScan will provide UBS with a rolling written forecast of LifeScan’s expected requirement for Products during the following 12 months; provided, the first month of such forecast shall be deemed binding on LifeScan and the balance of such written forecast shall be non binding. On a quarterly basis, UBS will provide LifeScan with details of its capacity limitations (the “UBS Capacity Limitation”). LifeScan agrees not to order quantities of Product greater than the UBS Capacity Limitation. For clarification purposes only, if there is a reduction in the UBS Capacity Limitation which LifeScan considers arbitrary and capricious, it shall be referred to the Joint Steering Committee for resolution.
	(b)		LifeScan is permitted to change the second month of its next forecast by plus or minus 25% and change the third and fourth month of such forecast by plus or minus 50% subject to the UBS Capacity Limitation.
	(c)		LifeScan will place any orders for the binding portion of any forecast given in accordance with clause 7.1(a) by written or electronic purchase order (or by such other means agreed to by the parties) to UBS, which will be placed in accordance with the lead-time requirements set out in clause 7.3. UBS acknowledges that LifeScan is not obligated to buy any specific amount of Products under this Agreement.

(d)

To the extent of any conflict or inconsistency between this Agreement and any purchase order, purchase order release, confirmation, acceptance or any similar document, the terms of this Agreement will prevail.

7.2

Inventory

	(a)		UBS will maintain inventories of Raw Materials sufficient for one month of LifeScan’s forecasted requirements. These quantities may be adjusted as agreed to by the Joint Steering Committee.
	(b)		UBS will maintain inventory of the Products on a first-in, first-out basis.

7.3		Lead Time
		UBS shall develop a supply chain system (e.g. KanBan levels, efficient processes) in cooperation with LifeScan and LifeScan authorized third parties that will allow, within the UBS Capacity Limitation, for a 30 day lead-time from a binding order until delivery.

7.4		Past Due Orders
		UBS shall notify LifeScan immediately in the event that any delivery date with respect to any Products shall not be met. In the event of any such delay in the delivery of Products, UBS shall, at its own expense, use its commercially reasonable efforts to expedite the delivery of any past due order, including but not limited to approving overtime, premiums to component suppliers, the difference between regular freight and premium freight or air freight and any other measures which may be necessary or useful in timely fulfilling LifeScan’s orders for Products hereunder.
7.5		Delivery

	(a)		Delivery and shipping terms for the Products will be FCA (Rowville, Victoria) (IncoTerms 2000), unless otherwise agreed to by the parties.
	(b)		All shipments must be accompanied by a packing slip which describes the articles, states the purchase order number and shows the shipment’s destination. As required, UBS agrees to promptly forward the original bill of lading or other shipping receipt for each shipment in accordance with LifeScan’s instructions.

7.6		Sub-Tier Component Supply Chain
		UBS shall be responsible for management of sub-tier suppliers for the Products and the performance of their obligations.

	(a)		Additionally, UBS shall provide a supply continuity plan for the Products manufactured by UBS to the Joint Steering Committee at least one hundred and eighty (180) days prior to the commercial launch of the Products or as soon as practicable prior to commercial launch.
	(b)		Upon reasonable notice, UBS shall provide LifeScan with access to supplier specifications, documentation, quality process audit records, supplier contracts, scorecards and costing information.

(c)

UBS shall work with the key sub-tier suppliers for the products to put in place written supply agreements. Among other customary terms, UBS shall negotiate to include in such supply agreements:

	(i)		No volume purchase commitments;
	(ii)		Provisions to allow assignment of the supply Agreement and all attendant rights to LifeScan or its designee without supplier’s consent;
	(iii)		Not less than 45 day payment terms; and
	(iv)		Rights to terminate the contract at UBS’ (or its assignee’s) discretion upon no more than 6 months’ notice.

In the event UBS is unable to obtain the Agreement of a sub-tier supplier to (i)-(iv) above, then it shall notify LifeScan prior to signing the agreement with such supplier in order to permit LifeScan the ability to obtain the agreement of the supplier to such provision.

7.7		Packaging for Shipment
		UBS will pack all Products ordered under this Agreement in a manner agreed by LifeScan as being suitable for shipment to the final destination and sufficient to enable the Products to withstand the effects of shipping, including handling during loading and unloading.
7.8		Quarterly Business Reviews
		The operations teams of UBS and LifeScan will have Quarterly business reviews to discuss quality performance, delivery performance, cost and other elements as needed.
7.9		Capacity
		UBS shall endeavour to provide, qualify, maintain and allocate to LifeScan sufficient capacity on a reasonable work and maintenance schedule to support at least 125% of LifeScan’s forecasted requirements. UBS shall review capacity versus total demand on at least a Quarterly basis and report findings to LifeScan’s management. UBS shall promptly notify LifeScan at any time the forecasted volume during the succeeding twelve (12) month period exceeds 75 percent of the manufacturing capacity.
7.10		Supply Risk
		In consultation with LifeScan, UBS shall develop and execute a second sourcing strategy for key raw materials.
8		Defective Products
8.1		Disposition of defective Products
		LifeScan shall within a reasonable time upon receipt of Product undertake a visual inspection for evidence of any damage to any shipping containers, vials or Product caused during transportation. Without prejudice to any other

remedy which LifeScan may have, UBS will replace at its own cost and expense, including reimbursement of freight and disposition costs incurred by LifeScan, the Products that fail to comply with the Products Specifications at the time of delivery FCA Rowville or have any defects that were in existence at the time of delivery FCA Rowville. LifeScan will notify UBS of the existence and nature of any non-compliance or defect within a reasonable time and UBS (or its nominee) will have a reasonable opportunity, not to exceed 10 Business Days from receipt of notification, to inspect such defective Products and provide LifeScan with detailed written instructions to return or dispose of such defective Products. The Joint Steering Committee shall agree on a returned goods authorization process. LifeScan shall have no obligation to pay for any of the Products that are subject to such a claim of non-compliance or defect provided if there is any dispute regarding the claim it shall be handled in accordance with Section 8.2. If UBS fails to so inspect and instructs LifeScan as to the disposition of such defective Products, LifeScan may dispose of such defective Products as it sees fit and UBS shall:

	(a)		reimburse LifeScan for all direct, out-of-pocket costs incurred by LifeScan in such disposition; and
	(b)		replace such defective Products at its own cost and expense,

		within 45 days of any disposal of Product or resolution of a LifeScan claim.
8.2		Independent testing

	(a)		If the parties disagree as to the Products’ conformance to the Products Specifications or whether the Products have such a defect, either party may deliver the Products to an independent third-party laboratory, mutually and reasonably acceptable to both parties, for analytical testing to determine whether the Products fail to comply with the Products Specifications at the time of delivery FCA Rowville or have any defects that were in existence at the time of delivery FCA Rowville. The parties agree to accept the results of such independent testing.
	(b)		All costs associated with such third-party testing shall be at LifeScan’s expense unless the tested Products are deemed by such third-party to fail to comply with the Products Specifications at the time of delivery FCA Rowville or have any defects that were in existence at the time of delivery FCA Rowville, in which case all such costs, including reimbursement of freight and disposition costs, shall be promptly paid by UBS.
	(c)		No inspection or testing of or payment for the Products by LifeScan or any third-party agent of LifeScan shall constitute acceptance by LifeScan thereof, nor shall any such inspection or testing be in lieu or substitution of any obligation of UBS for testing, inspection and quality control as provided in the Products Specifications or under applicable local, state, or federal laws, rules, regulations, standards, codes or statutes.

8.3

Corrective action

(a)

In the event any Governmental Authority having jurisdiction shall request or order, or if LifeScan shall determine that it is required to undertake, any corrective action with respect to any of the Products, including any recall, corrective action or field action, and the cause or basis of such recall or action to the extent it is attributable to:

	(i)		a breach by UBS of any of its warranties, representations, obligations or covenants contained in this Agreement; or
	(ii)		the negligence or wilful misconduct of UBS,

			then UBS shall be liable, and will reimburse LifeScan for the reasonable costs of such action.
	(b)		For the avoidance of doubt, the costs of such recall or action payable by UBS shall only include the reasonable direct costs actually expended by LifeScan in connection with such recall or action of Products manufactured by UBS and shall not include any consequential, punitive, exemplary, or multiplied damages. To the extent more than one party is manufacturing Product and it is difficult to identify the specific Product manufactured by UBS, then UBS shall only be responsible for the proportion of Product it manufactured out of the total amount of Product Sold by LifeScan in the prior Financial Year.

9		Inspection
9.1		Rights of Inspection
		LifeScan will have the right (directly or through an agent), upon reasonable notice to UBS and during regular business hours, to inspect and audit the facilities being used by UBS for production and storage of the Products to assure compliance by UBS (and will use reasonable efforts to cause its suppliers) with all applicable rules and regulations and with other provisions of this Agreement.
9.2		Obligations to rectify
		UBS will within 30 days remedy or cause the remedy of any deficiencies which may be noted in any such audit of UBS by LifeScan under clause 9.1 or, if any such deficiencies can not reasonably be remedied within such 30 day period, present to LifeScan a written plan to remedy such deficiencies as soon as possible. The failure by UBS to remedy or cause the remedy of any such deficiencies within such 30 day period or to present such a plan within such 30 day period and then use its best efforts to remedy or cause the remedy of such deficiencies in accordance with such written plan, as the case may be, shall be deemed a material breach of this Agreement.
9.3		Acknowledgment
		UBS acknowledges that the provisions of this clause 9 granting LifeScan certain audit rights shall in no way relieve UBS of any of its obligations under this Agreement, nor shall such provisions require LifeScan to conduct any such audits.

		Part 3: Services
10		Provision of Services
10.1		Supply of Initial Services
		UBS has been supplying the Initial Services. After the Effective Date, UBS will continue to supply the Initial Services to LifeScan in accordance with Schedule  2 and in accordance with and subject to the terms of this Agreement.
10.2		Supply of other Services

	(a)		From time to time the parties may agree that UBS will provide Services to LifeScan. For purposes of clarification, the Joint Steering Committee would agree on other Services, cost recovery and success fees based on milestones achieved. An example of further Services would be a request from LifeScan to create an additional manufacturing line in a LifeScan Manufacturing facility including payment of the reasonable costs of UBS and a reasonable success fee for qualification of the line. In each such event, the parties shall enter into a Services Addendum.
	(b)		During the term of each Services Addendum, UBS will supply the Services specified in the applicable Services Addendum to LifeScan.
	(c)		Each Services Addendum, when executed will be attached to this Agreement and form part of and be subject to the terms of this Agreement.
	(d)		In the event of a conflict between the terms of this Agreement and the terms of any Services Addendum, the terms of this Agreement will prevail, except to the extent that the applicable Services Addendum expressly and specifically states an intention to supersede this Agreement on a specific matter.
	(e)		If a Services Addendum provides for the amendment of a term of this Agreement, that amendment will be effective only in relation to that Services Addendum and, unless expressly specified to the contrary in the Services Addendum, will not otherwise amend this Agreement or operate in relation to any other Services Addendum or Product Addendum.

10.3		Manner of performing the Services
		UBS must provide the Services:

(a)

with due care and skill and in a timely manner;

	(b)		in a proper and efficient manner using that standard of skill, diligence, and prudence that would reasonably be expected from a prudent and experienced provider of services similar to the Services;
	(c)		in compliance with all laws, regulations and standards with which UBS is legally required to comply; and
	(d)		in compliance with all policies of LifeScan applicable to its business partners, of which it has been advised ahead of time in this Agreement or the Services Addendum.

11		Fees
11.1		Quarterly Service Fee

(a)

In consideration of the provision by UBS of Initial Services, LifeScan or its designee will pay to UBS:

	(i)		a service fee each Quarter (the “Quarterly Service Fee”) calculated in accordance with the remainder of this clause 11.1; and
	(ii)		upon achievement of a Milestone described in clause 11.2, the corresponding Milestone Amount.

(b)

The Quarterly Service Fee will be calculated as follows:

	(i)		for the first * [REDACTED] Covered Products Sold by LifeScan or its Affiliates to third parties during any Financial Year: * [REDACTED] per Covered Product;
	(ii)		for any Covered Products Sold by LifeScan and its Affiliates to third parties in excess of * [REDACTED] per Covered Product.

			For the avoidance of doubt, it is acknowledged the value of the initial service to LifeScan is not easily quantifiable and will fluctuate during the Term and the parties consider it best handled by a Quarterly Services Fee. Therefore, the Quarterly Service Fee will be payable regardless of who manufactures the Covered Products provided any Covered Products that have been provided to third parties as free samples or for testing purposes (including clinical trials) shall not be counted as “Sold” for purposes of calculating the Quarterly Service Fee.
			For the further avoidance of doubt, the calculation of the amount of Covered Products Sold shall begin at zero each Financial Year. The Quarterly Service Fee shall apply during the Interim Costing Period.
	(c)		Within 30 Business Days, of the end of each Quarter (or such lesser time subject to the then current capabilities of LifeScan), LifeScan will deliver to UBS a written statement setting forth:

(i)

the number of Covered Products Sold during the previous Quarter; and

(ii)

the calculation of the Quarterly Service Fee owed in respect of such Quarter.

(d)

Following receipt of the written statement from LifeScan pursuant to clause 11.1(c), UBS will provide to LifeScan an invoice for the Quarterly Service Fee amount reflected on LifeScan’s statement. LifeScan shall pay such invoice within forty-five (45) days of receipt.

11.2

Milestones

(a)

LifeScan shall pay to UBS an amount corresponding to the relevant Milestone below (the “Milestone Amount”) within 45 days of the relevant Milestone being achieved in each of the following countries:

	(i)		* [REDACTED];
	(ii)		* [REDACTED]; and
	(iii)		* [REDACTED].

Each Milestone Amount shall only be paid once.

11.3

Lump Sum Service Fee

	(a)		At any time before the Fee Conversion Reference Date, if LifeScan has not Sold Covered Products within two years from the Effective Date or ceases selling all Covered Products for eighteen months, LifeScan may, at its option, give notice of conversion of the Quarterly Service Fee to a one time lump sum fee of * [REDACTED] (Lump Sum Service Fee — A).
	(b)		If such Notice is given pursuant to clause 11.3(a):

	(i)		LifeScan’s obligations to pay Quarterly Service Fees will permanently cease at the end of the Quarter in which such notice was given; and
	(ii)		the Lump Sum Service Fee — A must be paid by LifeScan within thirty (30) days of the end of the Quarter in which such notice was given.

(c)

At any time after the Fee Conversion Reference Date, LifeScan may, at its option, give notice of conversion of the Quarterly Service Fee to UBS. After delivery of the notice of conversion to UBS, LifeScan shall only be required to pay the Quarterly Service Fee for the remainder of the Financial Year in which the notice of conversion was delivered to UBS. Promptly after the end of that Financial Year, LifeScan will calculate and pay within forty-five (45) days a one time lump sum fee (Lump Sum Service Fee — B) to be calculated by multiplying the total of the Quarterly Service Fee for the relevant Financial Year in which notice of conversion is given by the multiplier for such Financial Year as identified below:

	(i)		* [REDACTED];
	(ii)		* [REDACTED];
	(iii)		* [REDACTED];

	(iv)		* [REDACTED];
	(v)		* [REDACTED];
	(vi)		* [REDACTED]; and
	(vii)		* [REDACTED].

11.4		Audit Rights
		For the sole purpose of verifying amounts owed under this clause 11, UBS (or its designated audit expert) shall have the right no more than one time each Financial Year, at its own expense, to review the Financial Records for the preceding Quarters during the Term (other than those already reviewed in a prior audit) at the location(s) where the Financial Records are maintained by LifeScan upon thirty (30) days notice and during regular business hours. Results of such review shall be made available to LifeScan. Further, if the review reflects an overpayment to UBS, such overpayment shall be deducted from the next payment due to UBS. If the review reflects an underpayment to UBS, such underpayment shall be remitted by LifeScan to UBS within forty-five (45) days. If the underpayment is greater than five percent (5%) of the amount that was otherwise due for a Quarter, LifeScan shall reimburse UBS for the costs of such review. If no further payments are due to UBS (e.g. due to termination of this Agreement), then LifeScan shall pay to UBS the amount of such underpayment within forty-five (45) days of UBS’ provision to LifeScan of the results of UBS’ review.

12		Manufacturing Process Information and Other Intellectual Property
		As part of the Services to be provided by UBS to LifeScan, UBS undertakes to comply with the following provisions:

	(a)		Upon LifeScan’s request, UBS will provide LifeScan with a detailed written description of UBS’ process for the manufacture of the Products, including all underlying know-how relevant to the process and improvements thereto (collectively the Process), in sufficiently clear and detailed terms in a format mutually agreed by the parties so it can be readily followed to make the Products in the manner UBS considers most efficient.
	(b)		If UBS alters, modifies or changes the Process, UBS will promptly amend the description to include such alteration, modification or change.
	(c)		In addition to all the rights and licenses granted under the Development Agreement and License Agreement, UBS acknowledges and agrees that all rights to all inventions, improvements, discovery, trade secret, know-how, concept, idea and copyrightable works (including derivatives of UBS’ pre-existing copyrighted works) and the like created by UBS, its Affiliates or their officers, employers, and agents in and to the Process, Products, Initial Meters and improvements thereto (Agreement Intellectual Property Rights) will be owned by LifeScan and, if created

			under this Agreement, will vest in LifeScan immediately upon creation. UBS will, and will procure that its Affiliates, officers, employees and agents who have created any Agreement Intellectual Property Rights, execute an assignment in favour of LifeScan and any other documents reasonably requested by LifeScan. LifeScan hereby grants to UBS a non-revocable, worldwide, royalty-free, exclusive license, with the right to sub-license to make, have made, use and sell under and exploit in any way all rights in and to the Agreement Intellectual Property Rights outside LifeScan’s Field (as defined in the License Agreement).
	(d)		UBS will allow LifeScan (or its designee) access to UBS’ premises to observe and understand the Process.
	(e)		At LifeScan’s request, UBS agrees to assist LifeScan in the implementation of manufacturing capacity at a location of LifeScan’s choosing by entering into a Services Addendum. Assistance may include but not be limited to: procurement and commissioning of manufacturing equipment and processes, training for engineers, operators and other production support personnel and other activities required to produce Product. LifeScan agrees to pay UBS for its reasonable costs (approved in advance by LifeScan) incurred in connection with the implementation of this capacity and may include a success fee payable upon an agreed milestone.

		Part 4: Further Provisions
13		Sundry Obligations of UBS
13.1		Records
		UBS will keep and maintain proper records of the Products and Services provided to LifeScan. LifeScan may, upon reasonable prior notice, inspect such records at any time.
13.2		Reports
		The Joint Steering Committee will agree on any reports and the format they should be in. For example only, such reports may include monthly report setting out details of:

	(a)		all Products and Services supplied during the preceding month; and
	(b)		all Raw Materials, work-in-progress and finished goods held by UBS.

13.3

Equipment

(a)

UBS will provide equipment for the manufacture of strips to go into vials with a minimum capacity of * [REDACTED] strips per year (the “Original Line”) in Rowville, Victoria.

(b)

The Joint Steering Committee will determine whether additional equipment is required for the Original Line or for additional lines and which party is responsible for paying for such equipment.

13.4		Insurance
		UBS must use reasonable commercial efforts to obtain and maintain for the duration of this Agreement the insurances set forth in Appendix G:
14		Restrictions on UBS and UBI activities

(a)

During the Term of this Agreement, neither UBS nor UBI will, directly or indirectly, provide consultancy, advisory or other services to any third party in relation to:

	(i)		the measurement of analytes for purposes of diagnosing, managing, monitoring, prognosticating, treating or curing diabetes;
	(ii)		the collection and/or analysis of data for the purpose of diabetes management; or
	(iii)		the delivery of one or more therapeutic agents for the purpose of treating or managing abnormal glucose metabolism, including, without limitation, the delivery of insulin, insulin analogs, Glucagon-like proteins/peptides (GLPs), analogs of GLPs or GLP like hormones; or
	(iv)		the measurement of glucose in humans for any purpose, including, without limitation, tight glycemic control, (clauses (i)-(iv) being collectively, Restricted Purposes).

(b)

UBS and UBI acknowledge and agree that, other than the licenses expressly granted under this Agreement, the Development Agreement and the License Agreement, neither UBS nor UBI has any rights in any intellectual property owned by LifeScan or its Affiliates, including, without limitation, any intellectual property assigned to LifeScan under this Agreement, the Development Agreement or the License Agreement.

15		Representations and warranties
15.1		UBS Warranties
		UBS represents, warrants and covenants to LifeScan that:

(a)

all Products supplied in connection with this Agreement will be:

	(i)		of merchantable quality;
	(ii)		fit for the purpose intended by this Agreement;
	(iii)		free from defects in material and workmanship; and
	(iv)		manufactured and provided in accordance with the relevant Product Specifications and in compliance with this Agreement; Notwithstanding the above, UBS shall not be responsible for any breach of these warranties arising as a result of acts or omissions after delivery FCA Rowville.

(b)

it will comply with all applicable present and future laws, statutes, ordinances and regulations and requirements of any applicable Government Authority relating to:

	(i)		the design, manufacture and supply of the Products provided under this Agreement; and
	(ii)		the Services provided under this Agreement;

	(c)		the provision of the Products and Services to LifeScan by UBS will not involve the misappropriation of confidential information or trade secrets of any third party by UBS or its agents; and
	(d)		it and its Affiliates and each of their respective directors, officers, employees, agents and contractors who will provide the Products and or the Services have the requisite skill, knowledge and expertise to provide the Products and the Services in accordance with the provisions of this Agreement.

15.2		Execution and performance of agreement
		UBS and LifeScan each represents and warrants to the other that:

	(a)		it is a corporation or company duly organised, validly existing and registered under the laws of its place of incorporation;
	(b)		it has full right, power and authority to enter into and perform its obligations under this Agreement; and
	(c)		the performance of its obligations under this Agreement will not result in a violation or breach of, and will not conflict with or constitute a default under any agreement, contract, commitment or obligation to which such party or any of its Affiliates is a party or by which it is bound.

15.3		EXCLUSION OF OTHER WARRANTIES
		EXCEPT AS SET FORTH ABOVE, THE PARTIES TO THIS AGREEMENT MAKE NO OTHER REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESSED OR IMPLIED, WRITTEN OR ORAL, STATUTORY OR OTHERWISE, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE IN RESPECT OF THE PRODUCTS OR ANY WARRANTIES ARISING FROM COUSE OF DEALING OR USAGE OF TRADE AND THE PARTIES FURTHER AGREE THAT TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAWS, ANY CONDITIONS OR WARRANTIES IMPOSED BY LEGISLATION OR STATUTE ARE HEREBY EXCLUDED.

16		Compliance
16.1		Compliance with certain laws
		In the performance of its obligations under this Agreement, UBS agrees to comply with, and to cause its officers, employees, agents and contractors to comply with, the applicable provisions of all applicable laws, rules and regulations in force from time to time including all such legal requirements:

	(a)		prohibiting discrimination against any employee or applicant for employment because of race, colour, religion, sex or national origin;
	(b)		prohibiting discrimination against any employee or applicant for employment because of physical or mental handicap;
	(c)		establishing fair or minimum standards for workers; and
	(d)		the Trade Practices Act (Cth) 1974, the Therapeutic Goods Act (Cth) 1989, the Therapeutic Goods (Charges) Act 1989 and the Therapeutic Goods Amendment (Medical Devices) Act (Cth) 2002.

16.2

Compliance with Policy on the Employment of Young Persons

	(a)		UBS warrants that it and each of its officers have read and understand the Johnson & Johnson Policy on the Employment of Young Persons attached hereto as Appendix D (Policy).
	(b)		In the manufacture and supply of all the Products hereunder, UBS will employ young persons only as permitted by the Policy.
	(c)		UBS will permit representatives of LifeScan to enter UBS’ premises at any reasonable time, and UBS will ensure that representatives of LifeScan will be permitted to enter the premises of any subcontractor involved in the manufacture or supply of any of the Products at any reasonable time, in order to inspect relevant employment, health and safety records and to observe the manufacturing process.
	(d)		UBS will maintain the records necessary to demonstrate compliance with the Policy and will provide to LifeScan, upon LifeScan’s request, a written certification of such compliance annually during the term of this Agreement.
	(e)		If UBS fails to comply with this clause 16.2, then it shall be deemed a material breach of this Agreement by UBS.

16.3

Standards for Responsible External Manufacturing

	(a)		UBS and its officers have read and understand the Johnson & Johnson Standards for Responsible External Manufacturing (Standards) in effect as of the Effective Date and set out in Appendix J.
	(b)		LifeScan will have the right to audit UBS to determine compliance with the Standards in accordance with the provisions of clause 9.
	(c)		UBS will maintain the records necessary to demonstrate compliance with the Standards and shall provide to LifeScan, upon LifeScan’s request, a written certification of such compliance annually during the Term of this Agreement.

(d)

If UBS fails to comply with this clause 16.3, then it shall be deemed a material breach of this Agreement by UBS.

16.4

Files and Work papers

	(a)		All papers or electronic records, files, documents, work papers and other information in any form, whether marked “confidential” or not, provided by LifeScan, its employees, agents or affiliates pursuant to this Agreement (LifeScan Files and Work Papers) will remain the exclusive property of LifeScan.
	(b)		UBS and its subcontractors and agents will use LifeScan Files and Work Papers only for purposes of performing UBS’ obligations under this Agreement.
	(c)		LifeScan Files and Work Papers must be maintained in a manner that prevents their intentional or accidental disclosure to other clients of UBS.
	(d)		LifeScan Files and Work Papers will be kept in UBS’ possession only so long as it serves a necessary business purpose, the Services are ongoing and, in no case, longer than 30 days after the termination of this Agreement, unless otherwise agreed to in writing by an authorised agent of LifeScan.
	(e)		Upon 30 days after the termination of this Agreement, all LifeScan Files and Work Papers in the possession, custody or control of UBS, or its subcontractors and agents, will be returned to LifeScan unless directed otherwise by LifeScan. Thereafter, no copies are to be made or retained by UBS.
	(f)		UBS must promptly notify LifeScan prior to the production of subpoenaed LifeScan Files and Work Papers.
	(g)		Notwithstanding the above requirements, UBS may maintain records to the extent required by applicable statute, regulation or other law and UBS’ counsel may retain one copy of LifeScan Files and Work Papers for its records.

16.5		Compliance with Environment, Safety And Industrial Hygiene
		With respect to all environmental, safety and industrial hygiene matters related to UBS’ activities under this Agreement, UBS will:

	(a)		inform LifeScan promptly of any significant adverse event (e.g., fires, explosions, accidental discharges);
	(b)		inform LifeScan promptly of any allegations or findings of violations of applicable laws or regulations;
	(c)		allow LifeScan to inspect UBS’ facilities, such inspections to be at reasonable times and upon reasonable notice; and

(d)

implement promptly any corrective action which may be reasonably requested by LifeScan, including (without limitation) adhering to reasonable and significant elements of the environmental, safety and industrial hygiene program adhered to by LifeScan in its own operations.

17		Quality Agreement
		The parties shall enter into the Quality Agreement attached hereto as Appendix E.
18		Indemnities
18.1		UBS indemnity
		UBS shall indemnify and hold harmless LifeScan, its Affiliates and each of their respective officers, directors, employees and agents from and against any and all Losses that may be sustained, suffered or incurred by such indemnified parties in connection with a third party claim arising from or related to:

	(a)		a material breach by UBS or UBI of any warranty, representation, covenant or agreement made by UBS or UBI in this Agreement;
	(b)		the failure of any Product supplied by UBS to comply with the relevant Product Specifications;
	(c)		the negligence or wilful misconduct of UBS, UBI or their Affiliates pursuant to this Agreement; or
	(d)		the: (i) design; (ii) validation; or (iii) manufacture of the Products by UBS, including the presence of any defects or hidden defects in the Products except where UBS was acting at the express written direction of LifeScan;

		provided that UBS will not be liable for any Losses to the extent that they arise from (i) the negligence or wilful misconduct of LifeScan or its Affiliates or (ii) any breach by LifeScan of any warranty, representation, covenant or agreement made by LifeScan in this Agreement; and further provided notwithstanding any other provision of this Agreement, the obligation of UBS to indemnify LifeScan under this clause 18.1 shall terminate immediately upon termination of this Agreement other than with respect to matters where prior to the date of termination the indemnification procedures in clause 18.3 had already commenced.
18.2		Indemnification by LifeScan
		LifeScan shall indemnify and hold harmless UBS and its Affiliates and each of their respective officers, directors, employees and agents from and against any and all Losses that may be sustained, suffered or incurred by such indemnified parties in connection with a third party claim arising from or related to:

(a)

a material breach by LifeScan of any warranty, representation, covenant or agreement made by LifeScan in this Agreement;

	(b)		the negligence or wilful misconduct of LifeScan or its Affiliates pursuant to the Agreement;
	(c)		the (i) design of any meter (ii) validation of any meter (iii) manufacture of any meter or (iv) sale of any meter, including any defects or hidden defects resulting therefrom; or
	(d)		any claims that the Products and/or meter infringes or violates the intellectual property rights of any third party in the Territory;

		provided, that LifeScan will not be liable for any Losses to the extent that they arise from (i) the negligence or wilful misconduct of UBS or its Affiliates or (ii) any breach by UBS or UBI of any warranty, representation, covenant or agreement made by UBS or UBI in this agreement.
18.3		Indemnification procedures
		Each indemnified party agrees to give the indemnifying party prompt written notice of any matter upon which such indemnified party intends to base a claim for indemnification (an Indemnity Claim) under this clause 18. With respect to any Indemnity Claim relating solely to the payment of money damages and which could not result in the indemnified party becoming subject to injunctive or other equitable relief or otherwise adversely affect the business of the indemnified party in any manner, and as to which the indemnifying party shall have acknowledged in writing the obligation to indemnify the indemnified party hereunder, the indemnifying party shall have the right to control the defense of such claim, subject to the indemnified party’s ability to participate in the defense at its own expense with its own counsel or to control the proceedings if the indemnifying party is unable or unwilling to do so. The indemnifying party shall not have the right to settle any claim without the indemnified party’s written consent; provided, that the indemnifying party shall have the right to settle such a claim without consent if (i) the settlement involves only the payment of money damages and does not involve any equitable relief or any conditions that could adversely affect the business of the indemnified party in any manner and (ii) the settlement includes a complete release of the indemnified party from such claim.
18.4		Other Product Liability Claims
		In the case of any claim received by UBS from a third party for Losses related to personal injury or damage to property due to the use of any Product that is not subject to an indemnification obligation by UBS under clause 18.1, then UBS shall promptly notify LifeScan. LifeScan shall have the right to control the defense of such claim and have the right to settle any claim without UBS’ written consent.
18.5		Limitation of Liability
		NOTWITHSTANDING ANY OTHER TERM OF THIS AGREEMENT, THE PARTIES AGREE THAT TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NO PARTY WILL BE LIABLE TO THE OTHER FOR ANY SPECIAL, INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES ARISING IN CONNECTION WITH THIS AGREEMENT OR IN RESPECT OF ANY OF THE APPLICABLE PRODUCTS OR SERVICES.

19		Term and Termination
19.1		Term
		This Agreement commences on the Effective Date of signing and continues until terminated in accordance with this clause 19.
19.2		Termination for breach
		Either party may terminate this Agreement (without payment of any penalty or fee) with immediate effect by written notice to the other party if the other party is in material breach of a term of this Agreement and the material breach is not remedied within 90 days of written notice requiring it to do so.
19.3		Termination for insolvency and bankruptcy
		LifeScan may terminate this Agreement (without payment of any penalty or fee) with immediate effect by written notice to UBS if UBS undergoes an Insolvency Event or UBI undergoes a Bankruptcy Event. UBS may terminate this Agreement (without payment of any penalty or fee) with immediate effect by written notice to LifeScan if LifeScan undergoes a Bankruptcy Event.
19.4		Termination for change of control
		LifeScan may terminate this Agreement (without payment of any penalty or fee) upon thirty (30) days prior written notice if UBS or UBI undergoes a Change of Control. Notwithstanding the above, LifeScan shall not have a right to terminate this Agreement in accordance with the preceding sentence if (i) the LifeScan Manufacturing Line Date has occurred and (ii) UBS or UBI, as the case may be, are not being acquired by a third party that makes products that compete with the Initial Product.
19.5		Regulatory termination
		LifeScan may terminate this Agreement (without payment of any penalty or fee) on thirty (30) days prior written notice if LifeScan is prohibited from selling all Covered Products by a competent regulatory authority or is otherwise unable to sell Product(s) due to regulatory or legal constraints in the major markets in the Territory.
19.6		Additional LifeScan termination rights

	(a)		LifeScan may terminate this Agreement (without payment of any penalty or fee) upon thirty (30) days prior written notice of its reasonable determination that the Initial Product is not an approvable product.
	(b)		Prior to the Fee Conversion Reference Date, LifeScan may terminate this Agreement without cause upon prior written notice after payment of Lump Sum Service Fee — A to UBS in accordance with clause 11.3(a).
	(c)		After the Fee Conversion Reference Date, LifeScan may terminate this Agreement without cause upon 12 months prior written notice to UBS and in addition pay the Lump Sum Service Fee — B to UBS in accordance with clause 11.3(c).

19.7		Additional UBS termination rights
		UBS may terminate this Agreement by providing two years prior written notice to LifeScan (or such other period as may be agreed between the parties) if:

	(a)		the Lump Sum Services Fee — A or the Lump Sum Services Fee — B has been paid to UBS in which case LifeScan and UBS will negotiate a new transfer price for the relevant Covered Products provided any failure to reach agreement will be handled in accordance with clause 20; or
	(b)		the parties fail to reach agreement in relation to any suspension or change to the Maximum Transfer Price as contemplated by clause 6.2(e).

		For the avoidance of doubt, UBS agrees that during the pendency of such two-year notice period prior to termination, it shall fully perform its obligations under this Agreement.
19.8		Consequences of termination

	(a)		If LifeScan terminates this Agreement under clause 19.6(b) or (c), it will pay the amount specified in Appendix H:
	(b)		In the event of termination of this Agreement due to UBS’ breach pursuant to clause 19.2 UBS acknowledges and agrees LifeScan shall have the option to require UBS to provide all the manufacturing assistance services listed in clause 12(e) to enable LifeScan promptly to put in place LifeScan’s own qualified manufacturing line it being understood (i) LifeScan shall at its expense acquire any equipment it requires for such line and (ii) such assistance shall be at the reasonable expense of UBS.
	(c)		In the event of termination of this Agreement by LifeScan (other than for UBS’ breach pursuant to clause 19.2), LifeScan shall purchase at book value all inventory of Products or components of Products, in each case relating solely to Products that have been ordered by LifeScan and solely to the extent that such inventory is saleable and in compliance with the applicable Product Specifications (Qualified Inventory); provided that, LifeScan shall not be obligated to pay for more than a six month supply (determined on the basis of orders submitted by LifeScan in the course of the six months preceding termination) of such inventory and components.
	(d)		In the event of termination of this Agreement by LifeScan for UBS’ breach pursuant to clause 19.2 or termination of this Agreement by UBS, LifeScan shall have the option to purchase at book value all or any portion of the Qualified Inventory.
	(e)		Termination of this Agreement for any reason shall not release either party hereto from any liability which at such time has already accrued or which thereafter accrues from a breach or default prior to such expiration or termination, nor affect in any way the survival of any other right, duty or obligation of either party hereto which is expressly stated elsewhere in this Agreement to survive such termination.

(f)

Upon termination of this Agreement, UBS shall transfer to LifeScan in an orderly and prompt fashion all records and data relating to the Products, including the device master record, device history record, design history file and all product inquiry records, and such records and data shall be the property of LifeScan. UBS shall also cooperate with LifeScan to achieve an orderly transition of the manufacturing operations for the Products to LifeScan or its designee.

20		Dispute Resolution
20.1		Mediation

	(a)		Any dispute, controversy or claim arising out of or related to this Agreement, or the interpretation, application, breach, termination or validity thereof, including any claim of inducement by fraud or otherwise, shall, before submission to mediation or arbitration, first be submitted for resolution to the Joint Steering Committee in accordance with clause 4.3(c). If the dispute is not resolved in accordance with that clause, it will then be mediated through non-binding mediation in accordance with The CPR Mediation Procedure then in effect of the International Institute for Conflict Prevention and Resolution (CPR) available at www.cpradr.org/m_proced.htm, except where that procedure conflicts with these provisions, in which case these provisions control. The mediation shall be conducted in New York City, Borough of Manhattan and shall be attended by a senior executive with authority to resolve the dispute from each of the parties.
	(b)		The mediator shall be neutral, independent, disinterested and shall be selected from a professional mediation firm such as JAMS or CPR.
	(c)		The parties shall promptly confer in an effort to select a mediator by agreement. In the absence of such an agreement within 10 days of initiation of the mediation, the mediator shall be selected by CPR as follows: CPR shall provide the parties with a list of at least 15 names from the CPR Panels of Distinguished Neutrals. Each party shall exercise challenges for cause, two peremptory challenges, and rank the remaining candidates within 5 working days of receiving the CPR list. The parties may together interview the three top-ranked candidates for no more than one hour each and, after the interviews, may each exercise one peremptory challenge. The mediator shall be the remaining candidate with the highest aggregate ranking.
	(d)		The mediator shall confer with the parties to design procedures to conclude the mediation within no more than 45 days after initiation. Under no circumstances may the commencement of arbitration under clause 20.2 be delayed more than 45 days by the mediation process specified herein absent contrary agreement of the parties.

	(e)		Each party agrees not to use the period or pendency of the mediation to disadvantage the other party procedurally or otherwise. No statements made by either side during the mediation may be used by the other or referred to during any subsequent proceedings.
	(f)		Each party has the right to pursue provisional relief from any court, such as attachment, preliminary injunction, replevin, etc., to avoid irreparable harm, maintain the status quo, or preserve the subject matter of the arbitration, even though mediation has not been commenced or completed.

20.2

Arbitration

	(a)		Any dispute, claim or controversy not resolved in accordance with Clause 20.1, will be submitted for resolution to arbitration pursuant to the rules then pertaining of the International Institute for Conflict Prevention and Resolution for Non-Administered Arbitration (available at http://www.cpradr.org/arb-intro.asp?M=9.3), or successor (CPR), except where those rules conflict with these provisions, in which case these provisions control. The arbitration will be held in New York City, Borough of Manhattan.
	(b)		The panel shall consist of three arbitrators chosen from the CPR Panels of Distinguished Neutrals (or, by agreement, from another provider of arbitrators) each of whom is a lawyer with at least 15 years experience with a law firm or corporate law department of over 25 lawyers or who was a judge of a court of general jurisdiction. In the event the aggregate damages sought by the claimant are stated to be less than $5 million, and the aggregate damages sought by the counterclaimant are stated to be less than $5 million, and neither side seeks equitable relief, then a single arbitrator shall be chosen, having the same qualifications and experience specified above. Each arbitrator shall be impartial and independent of the parties and shall abide by the Code of Ethics for Arbitrators in Commercial Disputes (available at http://www.adr.org/EthicsAndStandards).
	(c)		The parties agree to cooperate (1) to attempt to select the arbitrator(s) by agreement within 45 days of initiation of the arbitration, including jointly interviewing the final candidates, (2) to meet with the arbitrator(s) within 45 days of selection and (3) to agree at that meeting or before upon procedures for discovery and as to the conduct of the hearing which will result in the hearing being concluded within no more than nine (9) months after selection of the arbitrator(s) and in the award being rendered within 60 days of the conclusion of the hearings, or of any post-hearing briefing, which briefing will be completed by both sides within 45 days after the conclusion of the hearings.

	(d)		In the event the parties cannot agree upon selection of the arbitrator(s), the CPR will select arbitrator(s) as follows: CPR shall provide the parties with a list of no less than 25 proposed arbitrators (15 if a single arbitrator is to be selected) having the credentials referenced above. Within 25 days of receiving such list, the parties shall rank at least 65% of the proposed arbitrators on the initial CPR list, after exercising cause challenges. The parties may then interview the five candidates (three if a single arbitrator is to be selected) with the highest combined rankings for no more than one hour each and, following the interviews, may exercise one peremptory challenge each. The panel will consist of the remaining three candidates (or one, if one arbitrator is to be selected) with the highest combined rankings. In the event these procedures fail to result in selection of the required number of arbitrators, CPR shall select the appropriate number of arbitrators from among the members of the various CPR Panels of Distinguished Neutrals, allowing each side challenges for cause and three peremptory challenges each.
	(e)		In the event the parties cannot agree upon procedures for discovery and conduct of the hearing meeting the schedule set forth in paragraph c above, then the arbitrator(s) shall set dates for the hearing, any post-hearing briefing, and the issuance of the award in accord with the paragraph c schedule. The arbitrator(s) shall provide for discovery according to those time limits, giving recognition to the understanding of the parties that they contemplate reasonable discovery, including document demands and depositions, but that such discovery be limited so that the paragraph c schedule may be met without difficulty. In no event will the arbitrator(s), absent agreement of the parties, allow more than a total of ten days for the hearing or permit either side to obtain more than a total of 40 hours of deposition testimony from all witnesses, including both fact and expert witnesses, or serve more than 20 individual requests for documents, including subparts, or 20 individual requests for admission or interrogatories, including subparts. Multiple hearing days will be scheduled consecutively to the greatest extent possible.
	(f)		The arbitrator(s) must render their award by application of the substantive law of the State of New York and are not free to apply “amiable compositeur” or “natural justice and equity.” The arbitrator(s) shall render a written opinion setting forth findings of fact and conclusions of law with the reasons therefor stated. A transcript of the evidence adduced at the hearing shall be made and shall, upon request, be made available to either party. The arbitrator(s) shall have power to exclude evidence on grounds of hearsay, prejudice beyond its probative value, redundancy, or irrelevance and no award shall be overturned by reason of such ruling on evidence. To the extent possible, the arbitration hearings and award will be maintained in confidence.
	(g)		In the event the panel’s award exceeds $5 million in monetary damages or includes or consists of equitable relief, or rejects a claim in excess of that amount or for that relief, then the losing party may obtain review of the arbitrators’ award or decision by a single appellate arbitrator (the Appeal Arbitrator) selected from the CPR Panels of Distinguished Neutrals by agreement or, failing agreement within seven working days, pursuant to the selection procedures specified in paragraph d above. If CPR cannot provide such services, the parties will together select another provider of arbitration services that can. No Appeal Arbitrator shall be selected unless he or she can commit to rendering a decision within forty-five days following oral argument as provided in paragraph h. Any such review must be initiated within thirty (30) days following the rendering of the award referenced in f above.

	(h)		The Appeal Arbitrator will make the same review of the arbitration panel’s ruling and its bases that the U.S. Court of Appeals of the Circuit where the arbitration hearings are held would make of findings of fact and conclusions of law rendered by a district court after a bench trial and then modify, vacate or affirm the arbitration panel’s award or decision accordingly, or remand to the panel for further proceedings. The Appeal Arbitrator will consider only the arbitration panel’s findings of fact and conclusions of law, pertinent portions of the hearing transcript and evidentiary record as submitted by the parties, opening and reply briefs of the party pursuing the review, and the answering brief of the opposing party, plus a total of no more than four (4) hours of oral argument evenly divided between the parties. The party seeking review must submit its opening brief and any reply brief within seventy-five (75) and one hundred thirty (130) days, respectively, following the date of the award under review, whereas the opposing party must submit its responsive brief within one hundred ten (110) days of that date. Oral argument shall take place within five (5) months after the date of the award under review, and the Appeal Arbitrator shall render a decision within forty-five (45) days following oral argument. That decision will be final and not subject to further review, except pursuant to the Federal Arbitration Act.
	(i)		The parties consent to the jurisdiction of the Federal District Court for the district in which the arbitration is held for the enforcement of these provisions and the entry of judgment on any award rendered hereunder (including after review by the Appeal Arbitrator where such an appeal is pursued). Should such court for any reason lack jurisdiction, any court with jurisdiction shall act in the same fashion.
	(j)		Each party has the right before or, if the arbitrator(s) cannot hear the matter within an acceptable period, during the arbitration to seek from the appropriate court provisional remedies such as attachment, preliminary injunction, replevin, etc. to avoid irreparable harm, maintain the status quo, or preserve the subject matter of the arbitration.
	(k)		Each party hereto waives its right to trial of any issue by jury.
	(l)		Each party hereto waives any claim to punitive, exemplary or multiplied damages from the other.
	(m)		Each party hereto waives any claim of consequential damages from the other.
	(n)		Each party hereto waives any claim for attorneys’ fees and costs and prejudgment interest from the other.

21		Confidentiality and public announcements
21.1		Non-disclosure
		Each party must keep all Confidential Information of the other party confidential in the same manner that it applies to its own confidential information and must not use that Confidential Information except as necessary for the purposes of this Agreement or to exercise rights and obligations under this Agreement, the License Agreement or the Development Agreement. Confidential Information received by a party may also be disclosed or revealed to employees of that party or employees of its Affiliates who are under an obligation to keep confidential proprietary information, or to a party’s contractors, suppliers, consultants, advisors or customers under a similar obligation of confidentiality. Nothing herein is intended to prevent a party using confidential Information for purposes of seeking a patent application, or seeking or maintaining regulatory approvals of a Product or for regulatory compliance.
21.2		Exceptions
		Each party’s obligations under clause 21.1 do not apply to any information which:

	(a)		is known to the receiving party prior to being received from the disclosing party, as established by its written records;
	(b)		is or, without fault of the receiving party becomes, publicly known;
	(c)		is received by either party from a third party without an obligation of confidence and having a right to disclose the same;
	(d)		is developed by the receiving party independent of any disclosure of Information hereunder, as established by its written records; or
	(e)		is required to comply with a court or administrative subpoena or order, provided the receiving party, where reasonably practicable, gives the other timely notice of the contemplated disclosure and provides the disclosing party the opportunity to intervene to preserve the confidentiality of the Confidential Information.
	(f)		is required to be disclosed by law or the listing rules of a recognized stock exchange, provided the party using this exception shall have given, to the extent reasonably possible, not less than two calendar days prior notice to the other party to seek confidential treatment for any required disclosure.

21.3		Public Announcements
		The parties hereto covenant and agree that, except as provided for herein below, each will not from and after the date hereof make, issue or release any public announcement, press release, statement or acknowledgment of the existence of, or reveal publicly the terms, conditions and status of, the

		transactions contemplated herein, without the prior written consent of the other party as to the content and time of release of and the media in which such statement or announcement is to be made; provided, however, that in the case of announcements, statements, acknowledgments or revelations which either party is required by law or the listing rules of a recognised stock exchange by which it is bound, to make, issue or release, the making, issuing or releasing of any such announcement, statement, acknowledgment or revelation by the party so required to do so by law shall not constitute a breach of this Agreement if such party shall have given, to the extent reasonably possible, not less than two (2) calendar days prior notice to the other party, and shall have attempted, to the extent reasonably possible, to clear such announcement, statement, acknowledgment or revelation with the other party. UBS shall not use the name of LifeScan or the name of any of LifeScan’s Affiliates for advertising or promotional purposes without the prior written consent of LifeScan. In furtherance of the foregoing, UBS shall not originate any publicity or other announcement, written or oral, whether to the public, the press, the trade, LifeScan’s or UBS’ customers or otherwise, relating to this Agreement or the existence of an arrangement between the parties, without the prior written approval of LifeScan. Notwithstanding the above, it is contemplated by the parties that UBS may issue an announcement on or after the Effective Date and a redacted form of the Agreement will be filed by UBI with the United States Securities and Exchange Commission.
22		Notices
22.1		General
		A notice, demand, certification, process or other communication relating to this Agreement must be in writing in English and may be given by an agent of the sender.
22.2		How to give a communication
		In addition to any other lawful means, a communication may be given by being:

	(a)		personally delivered;
	(b)		left at the party’s current address for notices;
	(c)		sent to the party’s current address for notices by pre-paid international courier, ordinary mail or pre-paid airmail, as applicable; or
	(d)		sent by fax to the party’s current fax number for notices.

		Notwithstanding the above, any written notice actually received by a party shall be deemed sufficient for purposes of this clause.
22.3		Particulars for delivery of notices

(a)

The particulars for delivery of notices are initially:

		LifeScan
		Address:		1000 Gibraltar Drive, Milpitas, CA 95035-6312, USA

		Fax:		1 ###-###-####
		Attention:		Worldwide Vice President, Business Development
		With a copy to:
		Address:		Johnson & Johnson,
				One Johnson & Johnson Plaza, New Brunswick, NJ 08933, USA
		Fax:		1 ###-###-####
		Attention:		Associate General Counsel, Medical Device & Diagnostics
		UBI
		Address:		1 Corporate Avenue,
				Rowville, Victoria 3178
		Fax:		61 3 9213 9099
		Attention:		Chief Executive Officer
		With a copy to:
		Address:		Venable LLP,
				8010 Towers Crescent Drive, Suite 300, Vienna, Virginia 22182, USA
		Fax:		1 ###-###-####
		Attention:		Elizabeth Hughes, Esq.

(b)

Each party may change its particulars for delivery of notices by notice to each other party.

		UBS
		Address:		1 Corporate Avenue,
				Rowville, Victoria 3178
				Australia
		Fax:		61 3 9213 9099
		Attention:		Chief Executive Officer
		With a copy to:
		Address:		PFM Legal,
				Level 12, 117 York Street,
				Sydney NSW 2000
		Fax:		61 2 9267-8196
		Attention:		Cameron Billingsley

(c)

Each party may change its particulars for delivery of notices by notice to each other party.

22.4		Communications by post or international courier
		Subject to clause 22.6, a communication is given if posted or couriered:

	(a)		within Australia to an Australian address, three Business Days after posting; or
	(b)		in any other case using the post, ten Business Days after posting; or.
	(c)		three business days after delivery to a recognized international courier.

22.5		Communications by fax
		Subject to clause 22.6, a communication is given if sent by fax, when the sender’s fax machine produces a report that the fax was sent in full to the addressee. That report is conclusive evidence that the addressee received the fax in full at the time indicated on that report.
22.6		After hours communications
		If a communication is given:

	(a)		after 5.00 pm in the place of receipt; or
	(b)		on a day which is a Saturday, Sunday or bank or public holiday in the place of receipt,

		it is taken as having been given at 9.00 am on the next day which is not a Saturday, Sunday or bank or public holiday in that place.
22.7		Process service
		Any process or other document relating to litigation, administrative or arbitral proceedings relating to this Agreement may be served by any method contemplated by this clause 22 or in accordance with any applicable law.
23		Force Majeure
23.1		Force Majeure Event

	(a)		If either party is prevented from performing any of its obligations under this Agreement due to a Force Majeure Event, such non-performing party will not be liable for breach of this Agreement with respect to such non-performance to the extent any such non-performance is due to a Force Majeure Event.
	(b)		Such non-performance will be excused for three months or as long as such event shall be continuing (whichever occurs sooner), provided that the non-performing party gives immediate written notice to the other party of the Force Majeure Event.
	(c)		Such non-performing party must use all reasonable endeavours to remedy the Force Majeure Event and to resume performance of its affected obligations as soon as practicable.

23.2

Failure to supply

(a)

Notwithstanding the provisions of clause 23.1, in the event that UBS is unable or unwilling or fails to supply any of the Products in such quantities as LifeScan requests and in compliance with the required delivery periods and subject to the UBS Capacity Limitation (whether due to the occurrence of a Force Majeure Event or otherwise), then:

	(i)		UBS will make available to LifeScan or its designee access to any technical and proprietary materials, information and techniques necessary or helpful for LifeScan to procure required raw materials or produce or arrange an alternative supplier of the Products; and
	(ii)		UBS will provide advice and consultation at its facilities or the facilities of any alternate supplier of the Products.

	(b)		Notwithstanding anything to the contrary contained in this Agreement, in the event that LifeScan shall make or have made the Products, pursuant to this clause 23.2, LifeScan will be permitted to disclose to any third party any Confidential Information as is reasonably necessary in connection with such activities (subject to such third party agreeing in writing to be bound by the terms of clause 21)
	(c)		If LifeScan gives an order within the UBS Capacity Limitation and UBS has an inability, unwillingness or failure to supply Product which conforms with the applicable Product Specifications within the relevant delivery periods and this occurs more than three times in any Quarter (unless due to a Force Majeure Event), such inability, unwillingness or failure shall be deemed a material breach of this Agreement.

24		Guarantee
24.1		Guarantee and Indemnity
		In consideration of LifeScan entering into this Agreement at the request of UBI (the receipt and good value of which is acknowledged by UBI), UBI irrevocably and unconditionally:

	(a)		guarantees to LifeScan the due and punctual observance and performance of all the obligations of UBS under this Agreement (including any warranties, covenants and indemnities given in favour of LifeScan); provided that in the event this guarantee is enforced and UBI is obligated to performance such obligations, then in such event LifeScan hereby grants to UBI all of the same rights granted to UBS under this Agreement solely to enable UBI to perform its obligations in this Agreement;
	(b)		without limiting clause 24.1(a), guarantees the due and punctual payment to LifeScan of all money due or which becomes due from UBS under this Agreement or arising out of breach by UBS of the terms, obligations, warranties and conditions contained in or implied in this Agreement; and

(c)

as a separate and independent principal obligation, indemnifies LifeScan against any Losses incurred or suffered by LifeScan which arise from any default by UBS in the performance of any obligations under this Agreement or from any express or implied obligations of UBS in this Agreement being unenforceable.

24.2		Survival
		The liability of UBI under clause 24.1 will not be released or discharged (in whole or in part) by:

	(a)		any time, concession, waiver or other indulgence being given by LifeScan to UBS (or any surety) for or in relation to the observance or performance of UBS’ obligations under this Agreement provided UBI shall have the benefit of any time, concession, waiver or other indulgence actually granted by LifeScan to UBS;
	(b)		any other security or contractual obligations to secure the performance of UBS’ obligations under this Agreement being or not being taken, held, renewed, varied or enforced by LifeScan or such security being void, defective, informal or unenforceable;
	(c)		all or any of UBS’ obligations under this Agreement being discharged otherwise than by their due performance or by this Agreement being terminated by LifeScan by due exercise of its rights under this Agreement;
	(d)		an Insolvency Event affecting UBS;
	(e)		the sale or other disposal of some or all of the shares in UBS which are owned by UBI; or
	(f)		anything done or omitted to be done by LifeScan or by anything else which, but for this clause 24.2, might operate to release wholly or partially or discharge or otherwise exonerate UBI from its liability under this guarantee and indemnity.

24.3		Continuing Guarantee
		The guarantee and indemnity given under this clause 24:

	(a)		is a continuing guarantee and indemnity and will remain in force until the whole of the obligations of UBS have been duly performed and satisfied in full;
	(b)		is irrevocable; and
	(c)		constitutes a separate and independent obligation of UBI.

24.4		Remedy
		LifeScan may enforce the guarantee and indemnity given under this clause 24 without first making any demand or taking any action or proceedings to enforce its rights or remedies against UBS.

page 45

24.5		Reinstatement
		The obligations of UBI under this clause 24 will continue to be effective or will be reinstated if, at any time any amount under this Agreement is avoided or any payment must be replaced or restored, either in whole or in part, by UBS for any reason whatsoever and the liability of UBI will extend to any such payment as if that payment had not been made.
24.6		Warranties
		UBI represents and warrants that:

	(a)		it has full power and authority to enter into this Agreement and has taken all necessary action to authorise the execution, delivery and performance of this Agreement in accordance with its terms;
	(b)		this Agreement constitutes a legally valid and binding obligation of UBI enforceable in accordance with its terms; and the execution, delivery and performance of this Agreement by UBI will not violate any provision of:

	(i)		any law or any order or decree of any applicable Government Authority;
	(ii)		the certificate of incorporation or bylaws of UBI; or
	(iii)		any encumbrance or other agreement which is binding on UBI.

25		GST
25.1		Construction
		In this clause 25:

	(a)		words and expressions which are not defined in this Agreement but which have a defined meaning in GST Law have the same meaning as in the GST Law; and
	(b)		GST Law has the same meaning given to that expression in the A New Tax System (Goods and Services Tax) Act 1999.

25.2		Consideration GST exclusive
		Unless otherwise expressly stated, all prices or other sums payable or consideration to be provided under this Agreement are exclusive of GST.
25.3		Payment of GST
		If GST is payable by a supplier or by the representative member for a GST group of which the supplier is a member, on any supply made under this Agreement, the recipient will pay to the supplier an additional amount equal to the GST payable on the supply. Notwithstanding the above, Section 38-185 of the GST Law provides a supply of goods exported from Australia within 60 days of invoice or payment is not required to pay GST. The parties will cooperate to export any Products within 60 days of invoice or payment for such Products.

page 46

25.4		Timing of GST payment
		The recipient will pay the amount referred to in clause 25.3 in addition to and at the same time that the consideration for the supply is to be provided under this Agreement.
25.5		Tax invoice
		The supplier must deliver a tax invoice or an adjustment note to the recipient before the supplier is entitled to payment of an amount under clause 25.3. The recipient can withhold payment of the amount until the supplier provides a tax invoice or an adjustment note, as appropriate.
25.6		Adjustment event
		If an adjustment event arises in respect of a taxable supply made by a supplier under this Agreement, the amount payable by the recipient under clause 25.3 will be recalculated to reflect the adjustment event and a payment will be made by the recipient to the supplier or by the supplier to the recipient as the case requires.
25.7		Reimbursements
		Where a party is required under this Agreement to pay or reimburse an expense or outgoing of another party, the amount to be paid or reimbursed by the first party will be the sum of:

	(a)		the amount of the expense or outgoing less any input tax credits in respect of the expense or outgoing to which the other party, or to which the representative member for a GST group of which the other party is a member, is entitled; and
	(b)		if the payment or reimbursement is subject to GST, an amount equal to that GST.

26		General
26.1		Duty

	(a)		UBS as between the parties is liable for and must pay all Victorian stamp duty (including any fine or penalty except where it arises from default by the other party) on or relating to the execution of this Agreement, or any document executed under it.
	(b)		If a party other than UBS pays any Victorian duty (including any fine or penalty) on or relating to the execution of this Agreement, or any document executed under it, UBS must pay that amount to the paying party on demand.
	(c)		It is acknowledged by the parties that none of the payments provided for under this Agreement are intended to be or are in fact in the nature of royalties, but rather are in the nature of payments for products and services.

page 47

(d)

LifeScan shall be entitled to deduct or withhold taxes where required by applicable law. UBS shall provide LifeScan as reasonably requested thereafter any tax documentation required to reduce or eliminate such deduction or withholding. LifeScan shall provide UBS with proof of payment of any taxes withheld or deducted pursuant to this clause.

26.2		Legal costs
		Except as expressly stated otherwise in this Agreement, each party must pay its own legal and other costs and expenses of negotiating, preparing, executing and performing its obligations under this Agreement.
26.3		Amendment
		No modification, change or amendment to this Agreement shall be effective unless in writing signed by each of the parties hereto.
26.4		Waiver and exercise of rights

	(a)		A single or partial exercise or waiver by a party of a right relating to this Agreement does not prevent any other exercise of that right or the exercise of any other right.
	(b)		A party is not liable for any loss, cost or expense of any other party caused or contributed to by the waiver, exercise, attempted exercise, failure to exercise or delay in the exercise of a right.

26.5		Rights cumulative
		Except as expressly stated otherwise in this Agreement, the rights of a party under this Agreement are cumulative and are in addition to any other rights of that party.
26.6		Consents
		Except as expressly stated otherwise in this Agreement, a party may conditionally or unconditionally give or withhold any consent to be given under this Agreement and is not obliged to give its reasons for doing so.
26.7		Governing law and jurisdiction
		This Agreement is governed by and is to be construed in accordance with the laws applicable in the State of New York, USA, without giving effect to any provisions thereof that would cause the application of the laws of any other jurisdiction.
26.8		Assignment
		This Agreement may not be assigned by LifeScan without the prior written consent of UBS, except that LifeScan may with prior written notice to UBS assign all or a portion of its rights and/or obligations hereunder to any of its Affiliates or to a successor, acquirer or licensee to the portion of its business to which this Agreement pertains without consent. UBS acknowledges that LifeScan has entered into this Agreement after consideration of the unique talent, experience and particular attributes of UBS to supply the Products. Therefore, this Agreement and all rights and obligations hereunder are

		personal to UBS and may not be assigned by UBS without the express written consent of LifeScan, which consent may be withheld or given in LifeScan’s sole discretion. Any such assignment or any attempted assignment in the absence of the prior written consent of LifeScan, shall be void and without effect at the option of LifeScan. Subject to the foregoing terms of this clause 26.8, this Agreement shall bind and inure to the benefit of the parties hereto and their respective permitted successors and assigns.
26.9		Counterparts
		This Agreement may consist of a number of counterparts and, if so, the counterparts can be executed separately by each party but taken together shall constitute one document.
26.10		Entire understanding

	(a)		This Agreement contains the entire understanding between the parties as to the subject matter of this Agreement.
	(b)		All previous negotiations, understandings, representations, warranties, memoranda or commitments concerning the subject matter of this Agreement are merged in and superseded by this Agreement and are of no effect. No party is liable to any other party in respect of those matters.
	(c)		No oral explanation or information provided by any party to another:

	(i)		affects the meaning or interpretation of this Agreement; or
	(ii)		constitutes any collateral agreement, warranty or understanding between any of the parties.

26.11		Severability
		In the event that any one or more of the provisions (or any part thereof) contained in this Agreement or in any other instrument referred to herein, shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, then to the maximum extent permitted by law, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement or any other such instrument. Any term or provision of this Agreement which is invalid, illegal or unenforceable in any jurisdiction shall, to the extent the economic benefits conferred by this Agreement to both parties remain substantially unimpaired, not affect the validity, legality or enforceability of any of the terms or provisions of this Agreement in any other jurisdiction.
26.12		Survival
		Clauses 9.1, 12, 13.4, 17, 18, 19, 20, 21, 22, 24, 25 and 26 shall survive the termination of this Agreement in accordance with the respective terms thereof. In addition, any other clauses of this Agreement that are expressly stated to survive by their terms shall survive termination of this Agreement.
26.13		Relationship of parties
		The relationship of LifeScan and UBS established by this Agreement is that of independent contractors, and nothing contained herein shall be construed to

(a) give either party any right or authority to create or assume any obligation of any kind on behalf of the other or (b) constitute the parties as partners, joint venturers, co-owners or otherwise as participants in a joint or common undertaking.

26.14		LifeScan Affiliates
		LifeScan, its successors or assigns may delegate to any of its Affiliates the right to exercise any rights or obligations of LifeScan under this Agreement in which case LifeScan shall give prior notice to UBS, it being acknowledged and agreed that LifeScan, its successors or assigns shall be the sole party looked to by UBS for all intents and purposes under this Agreement.
		[The remainder of this Page left blank]

page 50

Schedule 1 — Initial Product Addendum

This Product Addendum (Product Addendum) to the Master Services and Supply Agreement dated [insert date of Master Agreement] between LifeScan, Inc., Universal Biosensors Pty Ltd and Universal Biosensors, Inc (Master Agreement) is entered into by and between LifeScan, Inc., a Californian corporation of 1000 Gibraltar Drive, Milpitas, CA 95035-6312, USA (LifeScan), Universal Biosensors Pty Ltd ACN 098 234 309, a company incorporated in Victoria, Australia of 1 Corporate Avenue, Rowville, Victoria 3178 Australia (UBS) and Universal Biosensors, Inc., a Delaware corporation of having its registered office at c/o Corporation Service Company 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808 USA (UBI).

The parties agree that this Product Addendum is to be attached to, and form part of the Master Agreement. In relation to the matters addressed in this Product Addendum, each of LifeScan and UBS agrees to be bound by all of the terms and conditions of the Master Agreement and makes the representations and warranties set forth in the Master Agreement expressed to be made by LifeScan or UBS, as the case may be. All capitalised terms used in this Product Addendum and not otherwise defined in this agreement shall have the meaning ascribed to such terms in the Master Agreement.

The parties further agree as follows:

1.

Price

	(i)		Base Year Standard Cost = * [REDACTED].
	(ii)		Maximum Transfer Price = * [REDACTED]

2.

Specifications below

page 51

Initial Product Specification

* [REDACTED]

REFERENCE DOCUMENTS

CE low voltage directive (EU): 73/23/EEC OJ C 284 of 2005-11-16

Modification: Directive 93/68/EEC [CE Marking]

APPLICABLE STANDARDS / GUIDANCE

[1] ISO15197:2003 In vitro diagnostic test systems — Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus.

[2] FDA 21 CFR §820.30 Design Control requirements.

[3] FDA Guidance for the Content of Pre-market Submissions for Software Contained in Medical Devices. May 11, 2005: http://www.fda.gov/cdrh/ode/guidance/337.pdf

[4] General Principles of Software Validation; Final Guidance for Industry and FDA Staff: http://www.fda.gov/cdrh/comp/guidance/938.pdf

[5] FDA Draft Guidance – Total Product Life Cycle for Portable Invasive Blood Glucose Monitoring Systems. October 24, 2006: http://www.fda.gov/cdrh/oivd/guidance/1603.pdf

[6] IEC60601-1-8:2006. Medical Electrical Equipment – Part 1-8: General requirements for basic safety and essential performance – Collateral Standard: General requirements, tests and guidance for alarm systems in medical electrical equipment and medical electrical systems.

[7] IEC 60068-2-64:1993, Environmental testing — Part 2: Test methods — Test Fh: Vibration, broad-band random (digital control) and guidance

[8] IEC 60068-2-27:1987, Basic Environmental Testing Procedures — Part 2: Test Methods — Test Ea and guidance: Shock.

[9] IEC 60721-3-7:2002, Classification of Environmental Conditions — Part 3-7: Classification of Groups of Environmental Parameters and Their Severities — Portable and Non-stationary Use.

[10] IEC 61010-1:2001, Safety requirements for electrical equipment for measurement, control, and laboratory use — Part 1: General requirements

page 52

Initial System Specification

* [REDACTED]

page 53

Executed as an Addendum to the Agreement by the duly authorized representative of each Party as of the date first above written.

Executed by LifeScan, Inc.			)
						Name
						Title

Executed by Universal Biosensors Pty Ltd			) )
Company Secretary/Director						Director
Name of Company Secretary/Director (print)						Name of Director (print)

Executed by Universal Biosensors, Inc.			)
						Name
						Title

page 54

Schedule 2 — Initial Services Addendum

For the purposes of regulatory approvals, LifeScan will be the legal manufacturer of the Initial System. UBS will facilitate the regulatory approvals of the Initial System by providing the following initial services to LifeScan. In addition, after approval of the Initial System, UBS will provide certain ongoing services in connection with the Initial System as set out below (the initial services and ongoing services for the Initial System shall be defined as the “Initial Services” for purposes of this addendum).

	1.		Design verification testing of the Initial System in accordance with all regulatory requirements necessary to market the Initial System in * [REDACTED].
	2.		Complete a Design History File for the Initial Product in accordance with all regulatory requirements necessary to market the Initial System in * [REDACTED]. LifeScan will review the Design History File to satisfy themselves that it complies with LifeScan internal pre-launch prerequisites.
	3.		Assist in the preparation and completion of the Initial Meter Design History File in conjunction with *[REDACTED] and LifeScan for the benefit of LifeScan. It is anticipated that specific items to be included in the DHF will include Initial Meter Design Input, Design Output (3-D mechanical drawings, Gerber files, firmware, and component specifications), Design Verification on production units (or documented production equivalent), Design Validation on production units (or documented production equivalent), and Design Transfer Summary. Design verification to include documented test methods and sample rationale and Design Transfer Summary to include documented rationale of meter design translated to production specification.
	4.		Assist in the preparation and completion of the Initial Control Solution Design History File in conjunction with *[REDACTED] and LifeScan for the benefit of LifeScan . It is anticipated that specific items to be included in the DHF will include Design Input, Design Output, Design Verification and Design Validation.
	5.		Work with LifeScan on a mutually agreed basis to provide documentation to assist LifeScan to prepare and perform clinical trials and regulatory submissions.
	6.		Work with LifeScan on a mutually agreed basis to provide documentation necessary to assist LifeScan to prepare product labelling for the Initial System.
	7.		Design and manage the procurement of the initial custom-designed process equipment.

page 55

	8.		Work together with LifeScan to assess data from the field and use the data to decide methods for adapting process and control methodology to improve product performance.
	9.		Manage the specification(s) and all engineering change processes to Initial Product production equipment at UBS’ facility.
	10.		Specify and control Initial Product component performance and requirements. Manage or assist in the qualification and approval of all changes to suppliers and materials for the Initial Product.
	11.		Support manufacturing to ensure all work instructions are appropriate.
	12.		Evaluate the appropriate scope of manufacturing the Initial Product and help manage any change in scope, i.e. outsource or bring in-house certain process steps.
	13.		Identify, validate and implement cost reductions and process improvement in manufacturing the Initial Product.
	14.		Work with LFS on a mutually agreed basis so that LFS may enter into supply agreements with suppliers of components comprising the Initial System.
	15.		Investigate causes of customer complaints with the Initial Product referred to UBS by LifeScan.
	16.		Work with LFS on a mutually agreed basis to implement design changes to the Initial Meter, Initial Control Solution, Initial System and Initial Product.
	17.		* [REDACTED]

page 56

Executed as an Addendum to the Agreement by the duly authorized representative of each Party as of the date first above written.

Executed by LifeScan, Inc.			)
			)
						Name
						Title

Executed by Universal Biosensors Pty Ltd			) )
Company Secretary/Director						Director
Name of Company Secretary/Director (print)						Name of Director (print)

Executed by Universal Biosensors, Inc		) )
				Name
				Title

page 57

Schedule 3 — LifeScan Relevant Patents

*[REDACTED]

*Confidential portions has been omitted and has been filed separately with the Securities Exchange Commission pursuant to a request for confidential treatment.

Executed as an agreement by the duly authorized representative of each Party as of the date first above written.

Executed by LifeScan, Inc.			)
			)
						Name
						Title

Executed by Universal Biosensors			)
Pty Ltd			)
Company Secretary/Director						Director
Name of Company Secretary/Director (print)						Name of Director (print)

Executed by Universal Biosensors, Inc			)
			)
						Name
						Title

Appendix A — Form of Product Addendum

Date

This Product Addendum (Product Addendum) to the Master Services and Supply Agreement dated [insert date of Master Agreement] October 2007 between LifeScan, Inc., Universal Biosensors Pty Ltd and Universal Biosensors, Inc. (Master Agreement) is entered into by and between LifeScan, Inc., a Californian corporation of 1000 Gibraltar Drive, Milpitas, CA 95035-6312, USA (LifeScan), Universal Biosensors Pty Ltd ACN 098 234 309, a company incorporated in Victoria, Australia of 103 Ricketts Road, Mount Waverley, Victoria 3149, Australia (UBS) and Universal Biosensors, Inc., a Delaware corporation of having its registered office at c/o Corporation Service Company 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808 USA (UBI).

The parties agree that this Product Addendum is to be attached to, and form part of the Master Agreement. In relation to the matters addressed in this Product Addendum, each of LifeScan, UBS and UBI agree to be bound by all of the terms and conditions of the Master Agreement and makes the representations and warranties set forth in the Master Agreement expressed to be made by LifeScan, UBS or UBI, as the case may be. All capitalised terms used in this Product Addendum and not otherwise defined in this agreement shall have the meaning ascribed to such terms in the Master Agreement.

The parties further agree as follows:

3. [Products]

4. [Price]

5. [Specifications]

6. [Minimum Shelf Life]

7. [Product Materials]

8. Term of Product Addendum

1.

This Product Addendum shall commence on [insert date] and shall continue for a period of [insert duration] from such date (Term).

Executed by LifeScan, Inc.			)
						Name
						Title

Executed by Universal Biosensors			)
Pty Ltd			)
Company Secretary/Director						Director
Name of Company Secretary/Director (print)						Name of Director (print)

Executed by Universal Biosensors, Inc			)
			)
						Name
						Title

Appendix B — Form of Services Addendum

Date

This Services Addendum (Services Addendum) to the Master Services and Supply Agreement dated [insert date of Master Agreement] October 2007 between LifeScan, Inc., Universal Biosensors Pty Ltd and Universal Biosensors, Inc. (Master Agreement) is entered into by and between [LifeScan, Inc, a Californian corporation of 1000 Gibraltar Drive, Milpitas, CA 95035-6312, USA (LifeScan)] and [Universal Biosensors Pty Ltd ACN 098 234 309, a company incorporated in Victoria, Australia of 1 Corporate Avenue, Rowville, Victoria 3178, Australia (UBS) and Universal Biosensors, Inc., a Delaware corporation of having its registered office at c/o Corporation Service Company 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808 USA (UBI).

The parties agree that this Services Addendum is to be attached to, and form part of the Master Agreement. In relation to the matters addressed in this Services Addendum, each of LifeScan, UBS and UBI agree to be bound by all of the terms and conditions of the Master Agreement and makes the representations and warranties set forth in the Master Agreement expressed to be made by LifeScan, UBS or UBI, as the case may be. All capitalised terms used in this Product Addendum and not otherwise defined in this agreement shall have the meaning ascribed to such terms in the Master Agreement.

The parties further agree as follows:

1.

Services

2.		Consideration
		UBS acknowledges that it will be remunerated for the Services to be provided under this Services Addendum by means of the fees to which it will be entitled pursuant to clause 11 of the Master Agreement.
3.		Term of Services Addendum
		This Services Addendum shall commence on [insert date] and shall continue for a period of [insert duration] from such date (Term).

Executed by LifeScan, Inc.			)
						Name
						Title